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ABSTRACT OF THE DISSERTATION
The Role of miR-155 and miR-15/16 in Natural Killer Cell Maturation and Function
by
Ryan Patrick Sullivan
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2014
Professor Todd A. Fehniger, Chair

Natural Killer (NK) cells are a crucial component of the immune system, with a role in both early
host defense against pathogens and tumor immunosurveillance. NK cells develop in the bone
marrow from a common lymphoid precursor, along with T and B cells, but undergo a separate
education process. Additional maturation in the periphery makes NK cells fully competent to
protect the host. NK cells protect the host via two primary effector pathways – direct cytotoxicity,
and indirect cytokine/chemokine production (e.g. IFN-γ), which shapes the subsequent adaptive
immune response. The importance of this role of NK cells in human health is highlighted by the
recurrence of herpesvirus infections in NK-deficient patients, as well as a clinical association
between low NK cell function and an increased risk of developing cancer.

Micro-RNAs (miRNAs) regulate numerous cellular functions. MiRNA genes are transcribed as
long primary (pri-miRNA) transcripts that are subsequently 'cropped' by the Drosha/Dgcr8
complex into precursor miRNAs (pre-miRNA) that have a characteristic stem-loop structure. The
pre-miRNA is exported to the cytoplasm where it is further processed by Dicer1, yielding a
mature 18-24 nucleotide miRNA. The mature miRNA is loaded into the RNA induced silencing
complex (RISC), a component of which is Argonaute-2 (Ago2), and binds to a semicomplementary segment of the 3’ untranslated region (UTR) of a target mRNA. The RISC
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directs downregulation of the protein levels of the targeted transcript, either through RNA
degradation, segregation from translational machinery, or translational inhibition. Murine and
human NK cells express more than 300 mature miRNAs. Here, we investigated the role of
global miRNA deficiency, as well as the specific elimination of two abundant miRNA families
(miR-155 and miR-15/16) in NK cells.

miR-155 is markedly upregulated following cytokine activation of human and mouse NK cells.
Surprisingly, mature human and mouse NK cells transduced to overexpress miR-155, NK cells
from mice with NK cell-specific miR-155 overexpression, and miR-155-/- NK cells all secreted
more IFN-γ compared to controls. Investigating further, we found that activated NK cells with
miR-155 overexpression had increased per cell IFN-γ with normal IFN-γ+ percentages, whereas
greater percentages of miR-155-/- NK cells were IFN-γ+. In vivo MCMV-induced IFN-γ expression
by NK cells in these miR-155 models recapitulated the in vitro phenotypes. We performed
unbiased RISC-Seq on WT and miR-155-/- NK cells, and found that mRNAs targeted by miR155 were enriched in NK cell activation signaling pathways. Using specific inhibitors, we
confirmed these pathways were mechanistically involved in regulating IFN-γ production by miR155-/- NK cells. These data indicate that miR-155 regulation of NK cell activation is complex, and
that miR-155 functions as a dynamic tuner for NK cell activation via both setting the activation
threshold as well as controlling the extent of activation in mature NK cells. In summary, miR155-/- NK cells are more easily activated than WT NK cells, through increased expression of
proteins in the PI3K, NF-κB, and calcineurin pathways, and miR-155-/- and 155-overexpressing
NK cells exhibit increased IFN-γ production through distinct cellular mechanisms.

The miR-15/16 family is a miRNA family that is highly expressed in resting NK cells. Utilizing an
NK cell-specific miR-15/16 deficient genetic model [15a/16-1LoxP-FlankedKnockOut (FKO)], we
identified a critical role for miR-15/16 family miRNAs in the normal maturation of NK cells in

vii

vivo, with a specific reduction in mature CD11b+CD27- NK cells in multiple tissues. The
mechanism responsible was a block in differentiation, since accelerated NK cell death was not
evident, and earlier intermediates of NK cell maturation were expanded. Further, we identified
Myb as a direct target of miR-15/16 in NK cells, with Myb expression increased in immature
15a/16-1FKO NK cells. Following adoptive transfer, immature 15a/16-1FKO NK cells exhibited
defective maturation, which was rescued by ectopic miR-15/16 expression or Myb knockdown.
Moreover, Myb overexpression resulted in defective NK cell maturation. Thus, miR-15/16
regulation of Myb controls the normal NK cell maturation program.
Collectively, these studies provide new insight into the diverse role of miRNAs in NK cells.
These investigations further our understanding of NK cell biology, including activation and
maturation, two processes vital to the function of these important immune cells.
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Chapter 1: Introduction

1

Natural Killer cells
Natural Killer (NK) cells are large, granular lymphocytes initially identified for their ability to kill
murine leukemia virus – infected tumor cells.1,2 This newly identified role for a “natural killer” was
eventually expanded to responses against viruses, bone marrow transplants, and certain
bacteria.3 The mechanism of killing was later found to be through the release of cytotoxic
granules containing perforin, proteoglycans, and serine proteases (granzymes). Today, we
understand NK cells as a critical component of the innate immune system, but much remains to
be learned about the processes by which they develop and become competent to kill and
network with other immune cells.
NK cell development
NK cells begin their development in the bone marrow from the common lymphoid progenitor,4
which also gives rise to T and B cells.5 However, unlike their lymphocyte brethren, NK cells do
not have rearranged TCR or BCR genes,6 and can be generated in the absence of RAG,7
suggesting they do not require gene rearrangement to function appropriately. Mouse NK cell
development in the bone marrow can be defined by the expression of number of surface
markers, including CD51 (integrin αv), DX5, NK1.1, NKp46, CD122, and the Ly49 molecules.8,9
In this model of NK cell development, NK cells develop by first upregulating CD122 (Stage 1),
followed by a simultaneous acquisition of NK1.1, CD94-NKG2, and CD51 (Stage 2). In the next
stage, NKp46 and CD27 (Stage 3) are expressed, followed by expression of CD16, Ly49, c-Kit,
and DX5 (Stage 4). CD122+NK1.1+NKp46+CD27+ (Stage 3-4, or peripheral Stage II) NK cells
are the earliest readily identifiable stage of NK cells in peripheral organs, and likely represents
the stage at which NK cells are first able to emigrate from the bone marrow. Alternatively, a very
rare early population could potentially leave the bone marrow and additional development and
maturation could take place in situ in the peripheral organs. NK cells at later stages of
maturation can also be found in the bone marrow, including those that have upregulated CD11b
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(Stage 5, or peripheral Stage III), and those that have downregulated CD27 (Stage 6, or
peripheral Stage IV). However, a recent study identified that nearly all the Stage IV NK cells that
are found in the bone marrow are associated with the sinusoidal bone marrow compartment,
and are not resident in the bone marrow.10 Thus, current models suggest that the latest stage of
resident NK cells in the bone marrow is the Stage III subset, and further maturation is required
in the periphery.
NK cell maturation
During and after exit from the bone marrow, NK cells continue to mature, a process governed by
a number of known and unknown factors. In the mouse, peripheral NK cell maturation can be
assessed by the use of surface markers including CD11b, CD16, CD27, CD43, c-Kit, and
KLRG1.9,11,12 NK cell maturation can be affected by loss of a number of transcription factors,
including Prdm1,13 Ets1,14 T-bet, and Eomes, as well as caloric restriction15 and neutrophil
depletion.16,17 In humans, the CD56brightCD16-/+ and CD56dimCD16+ subsets have been
suggested to be functionally “immature” and “mature”, respectively. Indeed, CD56bright NK cells
from umbilical cord blood have been shown to have the capacity to gain CD16 and KIR
expression after in vitro culture,18,19 and human fetal liver CD56bright NK cells have been shown
to acquire CD16 and KIR after adoptive transfer into a humanized mouse,20 while CD56dim NK
cells have not shown the capacity to differentiate back into CD56bright.
Increased maturation has been shown to be correlated with decreased expression of genes
associated with proliferation and cell cycle, as well as increased expression of genes associated
with functional competence, including genes involved in NK cell-mediated cytotoxicity, Fc
receptors, and the secretory pathway.12 Thus, the evidence supports a direct relationship of NK
cell maturation with NK cell functionality, including the release of granules and cytokine
secretion.

3

NK cell function
NK cells stochastically express a limited number (up to 11 expressed in C57BL/6 mice21 and 15
expressed in humans22) of germline-encoded receptors, known as the Ly49 in mice, and KIR in
humans. These molecules recognize MHC class I, and one of the first processes in NK cell
development, after acquisition of activating receptors, is the expression of a wide repertoire of
these highly polymorphic molecules, corresponding to 6,000-30,000 distinct NK cell phenotypes
per individual.23 During or after the cumulative acquisition of KIR/Ly49,24 NK cells with at least
one inhibitory KIR/Ly49 recognizing a self-MHC molecule become licensed;25 that is, more
functionally responsive to later stimulation, defined by an increased ability to recognize target
cells and to kill cells that have downregulated MHC-I (missing self) or upregulated activating
ligands (recognition of cellular stress). NK cell licensing also prevents inappropriate NK cell
activation, which could lead to autoimmune inflammation and disease. This process also
influences the graft-versus-leukemia effects of NK cells, by setting a threshold for activation.26
The problem of stochastic expression of the germline-encoded KIR/Ly49 loci, and the lack of
linkage to the MHC (each Ly49/KIR molecule recognizes only distinct subsets of MHC
molecules) is solved by licensing: in outbred mouse and human populations, licensing ensures
a poised, yet inhibited at rest, NK cell population that is able to rapidly respond to alterations in
activating ligands or MHC expression.
Like the TCR, the Ly49 and KIR surface receptors are capable of recognizing MHC-I;27,28
however, these molecules recognize the MHC in a mostly peptide-independent fashion,29
indicating that their purpose is to quantify MHC expression itself, rather than to survey for nonself peptides. In this way, NK cells function as a complement to the adaptive immune system, as
a common viral immune evasion tactic is to downregulate MHC I in an effort to “hide” from T cell
detection. This MHC downregulation, however, can render a target cell susceptible to NK cell-
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mediated killing (by directed release of granules of cytotoxic molecules), through the recognition
of missing self.30
NK cells can also be activated by cytokine-mediated activation of NK cells, which can lead to a
generalized secretion of inflammatory cytokines and an increased ability to kill after a
subsequent cellular stimulus, known as a “primed” state. The most well-understood cytokine
activators of NK cells include IL-2, IL-12, IL-15, and IL-18, though NK cells can be activated by
many more, and the most well-characterized molecules produced by NK cells include IFN-γ, IL1A, IL-22, CCL3, CCL4, CCL5, and TNFα.31
An NK cell’s decision to kill is a complicated process, and is governed by the integration of a
large number of activating and inhibitory signals mediated by a wide variety of surface receptors
and their intracellular signaling motifs and cascades, many of which are not entirely understood.
One of the leading theories integrating the various known aspects of NK cell activation is the
tuning or “rheostat” model.32 This model proposes that both activating and inhibitory signals
contribute to the regulation of NK cell reactivity by “tuning” up or down the responsiveness of the
NK cell. In this way, NK cells continually adapt to their environment by altering the level of
stimulation required to cross a continually changing activation threshold. This is supported by a
number of studies, including NK functional anergy after the transgenic overexpression of
activating receptor ligands,33 as well as transfer of NK cells from an MHC-I sufficient
environment into an MHC-I deficient environment, where after an initial brief period of activation,
NK cells rapidly adjust and become hypofunctional.34
While some of the molecular mechanisms responsible for the regulation of activation in NK cells
have been defined,35,36 our understanding of the control of these processes, as well as
processes in the development and maturation of NK cells, is incomplete. One potential method
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of regulation is miRNA-mediated regulation, in which miRNAs regulate the protein-level
expression of many proteins in NK cells, and thus regulate multiple facets of NK cell biology.
Micro-RNAs
Micro-RNAs (miRNAs) are a family of small (~22 nucleotide), non-coding RNAs that regulate a
wide variety of cellular functions by targeting the 3’UTR of mRNAs. This targeting leads to either
translational suppression or mRNA degradation, or both, the net effect of which is decreased
protein levels.37 miRNA genes are encoded in the genome and transcribed as primary (primiRNA) transcripts that are cropped by the Dgcr8/Drosha complex into precursor miRNA (premiRNA). These pre-miRNAs have a characteristic stem loop structure, consisting of both a 5’
and a 3’ side.38 This pre-miRNA is exported through exportin 5, with Ran-GTP involvement, to
the cytoplasm.39 Once in the cytoplasm, it is further processed by the Dicer complex, removing
the loop and yielding a mature 18-24 nucleotide miRNA duplex. Therefore, genetic disruption of
Dicer leads to decreased levels of all micro-RNAs, a global miRNA defect. In this way, miRNAs
as a group have been shown to have roles in numerous cell types, including lymphocytes,40–45
with specific roles for certain miRNAs in B and T cell development and functional responses.46
Through a process that is not entirely understood, this duplex is loaded into the RNA induced
silencing complex (RISC), containing the Argonaute proteins, and one strand of the duplex is
typically discarded, while the other remains bound to the RISC. In plants, this miRNA:RISC
complex often binds to perfectly complementary RNAs and leads to RNA degradation. In
mammals, target mRNAs are typically only semi-complementary, consisting of high-quality
pairing in the seed region (nucleotides 2-8 of the miRNA) as well as some additional pairing to
improve miRNA:mRNA stability. This presents numerous difficulties for bioinformatic targeting
prediction. The RISC complex, after binding to a target mRNA, directs downregulation of protein
levels by speeding up mRNA deadenylation and blocking translation by ribosomes.47
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miR-155
miR-155 is a miRNA that is encoded in the BIC non-coding RNA, which has previously been
shown to be overexpressed in human B cell lymphomas.48,49 The expression of BIC, and thus
miR-155, has been shown to be promoted by AP-1, and requires NF-kB.50 Sustained expression
has been shown to result in a myeloproliferative disease.51 It is induced in the macrophage
inflammatory response,52 dendritic cell development and apoptosis,53 and has been shown to
have a role in class-switching54 through prevention of AID function55 as well as normal germinal
center formation and immune responses.56,57 miR-155 has been shown to modulate a large
number of targets: Socs1,58 and especially SHIP1 (Inpp5d), a phosphatase involved in the
negative regulation of PI3K signaling,59,60 though its role in repressing these targets is highly
cell-context specific.61
miR-15/16
The miR-15/16 family is a highly conserved family of miRNAs,62 consisting of miR-15a, miR15b, miR-16, miR-195, miR-322, miR-424, miR-503, miR-497, and miR-1907. In lymphocytes,
miR-15a, miR-15b, and miR-16 comprise the vast majority of the total miR-15/16 sequence.
These miRNAs are highly expressed,63–65 and have been found to inhibit B cell proliferation,66
and promote cellular apoptosis.67 miR-15a, miR-15b, and miR-16 are transcribed from two
distinct genomic loci: the miR-15a/16-1 cluster (human chromosome 13, mouse chromosome
14; intronic to the DLEU2 gene, known to be deleted in chronic lymphocytic leukemia),68 and the
miR-15b/16-2 cluster (human chromosome 3, mouse chromosome 3; intronic to the SMC4
gene, with a putative function in the structural maintenance of chromatin).69 All three miRNAs
share a high degree of homology and predicted targets, and as family members, have complete
overlap in seed sequence, the main determinant of miRNA targeting specificity; thus, they likely
share the same mRNA targets.
miRNAs in NK cells
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Mature mouse NK cells express more than 300 mature miRNAs, as assessed by miRNA-SEQ
with orthogonal validation by RT-qPCR and microarray.65 These miRNAs can vary in expression
during maturation or during NK cell activation. For example, miR-223 decreases during
activation, and miR-155 increases during activation. miR-223 has been shown to target the
mouse GzmB 3’UTR, while miR-155 has been shown to target the 3’UTR of SHIP1. In
aggregate, miRNAs have been shown to have a role in NK cell survival and function,70 but these
studies typically have not excluded the potential for cell-extrinsic effects. A number of NK cell
miRNAs are expressed in common with B and T lymphocytes, including miR-181, miR-21, miR142, miR-15b, miR-16, miR-150, and let-7f, implying that these miRNAs are all essential for
lymphocyte development and/or functional programs. However, some miRNAs are more highly
expressed in NK cells, such as miR-21 and miR-23a, or are specifically lacking, such as miR10a. Thus, the roles for miRNAs in NK cells may be unique or different from those in other
lymphocytes. Prior to the work described here, the roles of miRNAs in NK cells were a complete
mystery.71 During the conduction of the experiments described here, the roles of some
individual lymphocyte miRNAs were assessed, including miR-29’s role in contributing to the
regulation of IFN-γ;72 miR-155’s role in repressing SHIP1,60,73 and miR-150’s role in NK cell
maturation;74 however, the roles of the vast majority of miRNAs expressed in lymphocytes have
yet to be elucidated.
Overview of Thesis
Thus, in order to examine the role of miRNAs in NK cells, we began by asking, “What are the
ramifications of global miRNA deficiency on NK cells?” Answering this question would provide
evidence to support the role of miRNAs as critical regulators of specific aspects of NK cell
development, survival, priming, triggering, or function. As a global deletion of Dicer, a key
processing enzyme in the miRNA pathway, is embryonic lethal, we chose to use the best NKselective model available at the time, the hCD2-Cre model. In this model, Cre is expressed only
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in cells that arise from the common lymphoid progenitor: T, B, and NK cells. By combining a
LoxP-flanked Dicer allele (Dicerfl/fl) and the hCD2-Cre, we generated Dicer-deficient, and thus
miRNA-deficient, NK cells. This is the focus of Chapter 3, where we found that miRNA-deficient
NK cells had decreased survival and increased function.
We next began to examine the role of specific miRNAs in NK cells, starting with miR-155. This
is the focus of Chapter 4. miR-155 is expressed in resting NK cells, albeit at modest levels.64,65
However, these levels are dramatically increased after cytokine activation. We thus focused on
miR-155 as a regulator of NK cell activation after cytokine stimulation, and found that miR-155
had a dual regulation on NK cell activation, with 155-/- NK cells having increased IFN-γ secretion
due to an increased percentage of IFN-γ+ NK cells without a change in per-cell expression, and
155-overexpressing NK cells producing more IFN-γ per cell. The cellular mechanism for miR155’s dual effect on IFN-γ was recapitulated in vivo during MCMV infection of 155-/- and 155FOE
mice. Notably, 155-/- mice had decreased MCMV titers, suggesting that the increased
functionality of 155-/- NK cells has a biologically significant impact on the early NK-mediated
anti-viral cytokine response. Utilizing RISC-Seq analysis of activated NK cells from WT and 155/-

mice, we identified and validated novel miR-155 mRNA targets in NK cells, including many

involved in activation pathways. We further used chemical inhibitors of multiple activation
pathways to eliminate IFN-γ production differences, indicating that miR-155 extensively
regulates molecules involved in NK cell activation, thereby regulating the NK cell activation
threshold and indicating a novel role for miR-155 in altering the NK cell activation threshold.
We next hypothesized that miR-15/16 was involved in maturation or survival, due to its high
expression. This is the subject of Chapter 5. We found that genetic deletion of one contributing
allele to the mature miR-15/16 pool (miR-15a/16-1) led to defective maturation, particularly from
the CD27+CD11b+ stage to the CD27+CD11b- stage, one of the final stages of NK cell
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maturation. miR-15/16 targets the transcription factor c-Myb, and through lentiviral reintroduction of c-Myb, we show that c-Myb overexpression is the causative factor of the
maturation defect in the miR-15a/16-1FKO NK cells, implying that c-Myb downregulation is a
crucial step in NK cell maturation.
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Chapter 2: Methods

11

Mice
All mice were bred and maintained in specific pathogen-free (SPF) housing, and all experiments
were conducted in accordance with the guidelines of and with the approval of the Washington
University Animal Studies Committee. Mice were utilized between 8-12 weeks of age for all
experiments. C57BL/6J, B6.RAG1-/-, B6.Cg-Tg(CD2-cre)4Kio/J [hCD2-Cre],75 B6.129X1Gt(ROSA)26Sortm1(EYFP)Cos/J [Rosa-LSL-YFP],76 B6.dicerflox/flox [Dicerfl/fl],40 B6.Cg-Mir155tm1.1Rsky/J
(155-/-)56 were obtained from Jackson Labs (Bar Harbor, ME). 155FOE mice were generated by
crossing Tg(Ncr1-iCre)265Sxl mice,77 with mice containing a miR-155 LoxP-STOP-LoxP
expression cassette knocked in to the Rosa locus.56 15a/16-1FKO mice were generated by
crossing either Tg(Ncr1-iCre)265Sxl mice,77 or B6.Cg-Tg(CD2-cre)4Kio/J,78 with mice containing
a LoxP-flanked miR-15a/16-1 allele,66 as well as a Rosa-LSL-YFP. In some experiments,
Nkp46iCre knock-in mice,9 were used instead of Tg(Ncr1-iCre)265Sxl, and had an equivalent
phenotype. CD45.1 congenic mice were obtained from the National Cancer Institute. RAG-/-γc-/mice were obtained from Taconic. All mice except for NSG were either generated on a C57BL/6
background, or backcrossed at least 10 times to B6.
Normal Human Donors
Healthy normal donor NK cells were obtained from platelet donors undergoing apheresis at the
Barnes Jewish Hospital apheresis center. Leukocyte reduction filters are obtained immediately
after apheresis, flushed, and fresh PBMC and NK cells were isolated as described.79 Use of
these cells was reviewed by the Washington University Human Research Protection Office and
was found to not constitute human subjects research.
Cell Lines
YAC-1, RMA, and RMA-S cells (kind gifts of W. Yokoyama) were maintained in R10 (RPMI1640, 10% FCS, 10mM HEPES, 1% NEAA, 1% sodium pyruvate, 1% L-glutamine, 1X
penicillin/streptomycin). 293T cells (a kind gift of M. Sands) were grown in D10 (DMEM, 10%
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FCS,

10mM

HEPES,

1%

NEAA,

1%

sodium

pyruvate,

1%

L-glutamine,

1X

penicillin/streptomycin).
MCMV infection and plaque assays
MCMV infections, stock preparations, and titering were performed as described previously.80–82
Mice were infected with 10,000-50,000 PFU MCMV (Smith Strain) intraperitoneally (i.p.), as
indicated. Some mice were injected with BrdU 4 days post-infection. 4 hours post-BrdU
injection, spleens were harvested and assessed using standard BrdU intracellular flow
cytometry.
Reagents and monoclonal antibodies
Endotoxin-free purified cytokines (rmIL-12, rmIL-15, rmIL-18, rhIL-12, rhIL-15, rhIL-18) were
obtained from Peprotech (Rocky Hill, NJ) and reconstituted in sterile PBS with 0.1% BSA.
CellTrace Violet was used to monitor cell division and was used according to the manufacturer’s
instructions (Invitrogen / Molecular Probes, Eugene, OR). AccuCount beads were used for
absolute cell number determinations via flow cytometry following the manufacturer's instructions
(Spherotech, Lake Forest, IL). Chemical inhibitors (Ly294002, BAY 11-7082, and cyclosporin A)
were obtained from EMD Millipore.
Antibodies
Anti-mouse mAbs were obtained from BD Biosciences (San Jose, CA): IFN-γ (XMG1.2), NK1.1
(PK136), NKp46 (29A1.4), CD3 (145-2C11), CD45 (30-F11), CD27 (LG.3A10), CD11b (M1/70),
CD19 (1D3), CD212 (114), CD132 (4G3), Gr-1 (RB6-8C5), Ki-67 (B56), Ly49A (JR9-318),
Ly49C/I (5E6), Ly49G2 (4D11), Ly49D (4E5), Ly49H (3D10), and pSTAT5 (47); eBioscience
(San Diego, CA): CD27 (LG.7F9), CD107a (1D4B), Ly49C/I/F/H (14B11), NKG2A (16a11),
NKG2ACE (20d5), CD94 (18d3), CD122 (TM-β1); Caltag: GzmB (GB12); BioLegend (San
Diego, CA): CD218a (BG/IL18Ra), CD226 (TX42.1); Santa Cruz Biotechnology: SLP-76 (C-20),
IKBKE (H-116), SHIP1 (P1C1), and β-actin (C4). Anti-Ly49C (4LO) was kindly provided by W.
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Yokoyama. anti-NK1.1 (PK136) and anti-CD16/32 (2.4G2) were purified by the Washington
University Antibody Production core from hybridoma supernatant. Anti-human antibodies were
obtained from Beckman Coulter: CD3 (UCHT1), CD56 (N901), CD158a,h (EB6B),
CD158b1,b2,j (GL183); BD Biosciences: CD16 (3G8), CD94 (HP-3D9); BioLegend: IFN-γ (B27).
Abs for immunoblots were obtained from Santa Cruz Biotechnology: c-Myb (C-19), SHIP1 (H300), IKBKE (H-116), SLP76 (C-20), and β-actin (C4). IL-15 was obtained from Peprotech.
Cell isolation and sorting
Mouse tissues (spleen, bone marrow, blood, liver) were isolated from 8-12 week old mice as
described.82,83 Briefly, single cell suspensions were generated from spleen (mechanical
disruption through a 70uM filter or glass tissue homogenizer), bone marrow (flushing tibia with
PBS), liver (mechanical disruption followed by Percoll gradient isolation), lung (mechanical
disruption and collagenase/DNAseI digestion), or blood (cardiac puncture). RBC lysis was
performed using ACK buffer (150mM NH4Cl, 10mM K2CO3, 0.1mM EDTA), and viable cell
numbers were determined by hematocytometer (trypan blue exclusion) or Nexcelom cellometer
(Nexcelom) with PI-exclusion. Blood is calculated as cells per mL of blood obtained.
RNA isolation and RT-qPCR
Cells were immediately lysed in TRIzol or TRIzol LS (Invitrogen, Carlsbad, CA) according to
manufacturers’ instructions. Total RNA was extracted as previously described,84 or using
Directzol (Zymo Research) according to manufacturer’s instructions. cDNA was generated from
RNA using either the TaqMan Reverse Transcription Kit with random primers or TaqMan
miRNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA) with specific primers
according to manufacturer’s instructions. Dicer1 excision in cDNA was detected by two
methods: 1) internal to the loxP sites or 2) primers external to the loxP sites. miRNA
quantification was detected by TaqMan miRNA Kit with specific primers/probe. All primers and
probes were manufactured by IDT (Coralville, IA) or ABI. Myb expression was detected in
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sorted NK cells using IDT PrimeTime Assay Hs.PT.56a.1442895, and normalized to 18S rRNA.
All mRNA cDNA samples were normalized to 18S rRNA, and all miRNA cDNA samples were
normalized to housekeeping small RNAs, sno135 (mouse) or RNU48 (human), using the ∆∆CT
method. All qPCR was performed on an ABI StepOne or 7300 machine.
Single Cell PCR
Bulk populations of YFP+ or YFP- NK cells were sorted as described above. These cells were
processed essentially as described.85 Briefly, individual cells were isolated and amplified using
the GenomiPhi v2 Whole Genome Amplification Kit (GE Healthcare, Piscataway, NJ). The
whole genome amplification product (1 µL) was then used in a multiplex PCR reaction to amplify
the wild type, floxed, or excised Dicer1 alleles, and the resulting products were analyzed by
agarose gel electrophoresis. Primers are available upon request.
Nanostring miRNA Expression Analysis
Total RNA was processed on a Nanostring (Seattle, WA) nCounter instrument using the mouse
miRNA Expression Assay Kit according to the manufacturer’s instructions. Data obtained were
then sequentially normalized to both housekeeping mRNA controls and positive miRNA-ligation
reaction controls of the assay to adjust for total RNA content and ligation efficiency,
respectively. This provides a normalized absolute count of 578 mature miRNAs present in the
total RNA pool. Non-specific mature miRNA probes (e.g. miR-720) defined by lack of expression
based on miRNA-SEQ were excluded from this analysis.65 MiRNAs from Dicer1fl/fl YFP+ NK cells
that were detected at 2 SD above background were divided into categories and further analyzed
for global miRNA fold change analysis by taking the geometric mean of each group of miRNAs.
mRNA microarrays
YFP+CD27+NK1.1+CD3- splenic NK cells were sorted from hCD2-Cre x 15a/16-1FKO mice or
the corresponding controls, and resuspended in TRIzol (Invitrogen). RNA was then isolated
using the Zymo DirectZol Kit (Zymo Research). RNA was amplified using the Ovation PicoSL Kit
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and run on an Affymetrix Gene1.0ST Chip by the SCC Molecular and Genomic Analysis (MGA)
Core. Results were analyzed in Partek, using RMA normalization.
Assessment of NK cell function and survival
Splenocytes (1x106) or sorted YFP+ NK cells (1x104) were cultured in 24-well plates (Corning,
Corning, NY) containing either K10 + YAC-1 at a 10:1 E:T Ratio, K10 + 10 ng/mL IL-12 and 100
ng/mL IL-15, or K10 + plate-bound anti-NK1.1 (PK136) for 8 hours as described;83,86 or in K10 +
5ng/mL IL-15 or 100ng/mL IL-15. Flow cytometry data were collected for cell surface markers
including CD107a and intracellular IFN-γ on a Beckman Coulter Gallios flow cytometer. Data
were analyzed using FlowJo (Tree Star Software, Ashland, OR) or Kaluza (Beckman Coulter,
Miami, FL). In some experiments, data are presented as percent maximal CD107a or IFN-γ
expression by normalizing to the condition with the highest intra-assay expression in YFP+ NK
cells to account for inter-experiment variability. For proliferation assays splenocytes were
stimulated as indicated after labeling in K10 with CellTrace Violet according to the
manufacturer’s instructions, and data analyzed using FlowJo (Tree Star Software, Ashland,
OR). For phospho-STAT5 assays, 1x106 splenocytes were cultured for 15 minutes in 5ng/mL IL15 before fixation and staining as described.87
IFN-γ ELISA
Sorted GFP+ (LV-GFP, LV-GFP/155), Cre+ (155FOE), or bulk (155-/-) NK cells were plated in
duplicate, and cultured for the indicated periods of time in cRPMI + 10% FBS + 10ng/mL each
indicated cytokine or immobilized antibody. Cell-free supernatants were collected and frozen at 80, thawed only once, and analyzed by ELISA from eBioscience according to the
manufacturer’s instructions.
Assessment of miRNA targeting of 3’ UTRs using luciferase sensor plasmid assays
Overexpression of mature miRNAs and luciferase sensor-plasmids were performed as
previously described.65 Briefly, psiCheck2 (Promega, Madison, WI) with the 3’ UTR of IFN-γ was
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cloned by amplification of the IFN-γ 3’ UTR from IFN-γ cDNA (a kind gift of M. Cooper). Two
miR-15/16 binding sites were disrupted in two sequential rounds of mutagenesis using the
QuikChange II Site-Directed Mutagenesis Kit (Agilent/Stratagene, Santa Clara, CA) following
the manufacturer’s instructions. MiRNA overexpression vectors were generated by sub-cloning
the pre-miRNA gene plus 200bp flanking genomic sequence into the pMND overexpression
vector (a kind gift of M. Sands).65 All primers used for cloning are available upon request. 293T
cells were co-transfected with 800 ng of each vector using Dharmafect Duo (Dharmacon,
Lafayette, CO) and grown for 48 hours in D10. Dual-glo luciferase assay (Promega, Madison,
WI) was then performed according to the manufacturer’s instructions on an LD400
luminescence detector (Beckman Coulter, Brea, CA). Renilla luciferase (experimental) was
normalized to Firefly luciferase (control) followed by comparison of Renilla/Firefly ratios of the
same psiCheck2 sensor plasmid co-transfected with an ‘empty’ GFP-only control vector. Overexpression was confirmed by GFP expression and RT-qPCR of miRNA samples.
IFN-γ stimulation assay / Inhibitor Assay
IFN-γ stimulation was performed as previously described.88 Licensing assays were performed as
described previously.89 For inhibition assays, IC50 values were obtained from the manufacturer,
or in cases in which the inhibitor had been tested in NK cells, were used at the previously
demonstrated value (cyclosporin A=35.7nM,90 BAY 11-7082 = 10µM (manufacturer), Ly294002
= 1.2µM 91). Conditions with NK cell toxicity were excluded.
Lentiviral Transduction
High titer MND-∆U392 lentivirus was generated using standard third generation packaging
systems, pseudotyped with VSV-G, in ultracentrifuged supernatants from 293T cells. Human NK
cells were purified from peripheral blood to >90% purity using RosetteSep (StemCell
Technologies, Vancouver, Canada). Mouse NK cells were sorted to >99% purity from RAG-/spleens. 1x106 human NK cells were cultured in cRPMI + 10% HAB Serum + 100ng/mL rhIL-15,
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while mouse NK cells were cultured in cRPMI + 10% FBS + 100ng/mL rmIL-15. Lentivirus was
then added at an MOI of 20, and the cells were centrifuged (“spinfected”) at 2,000 rpm, 30ºC, 45
minutes in a standard swinging bucket table-top centrifuge. Cells were cultured overnight at
37ºC in 5% CO2, and spinfection was repeated the next day (day 1). On day 2, media was
replaced by removing ½ media, taking care not to disturb the cells, and adding cRPMI +
10%FBS +10ng/mL rmIL-15 or HAB + 10ng/mL rhIL-15 as appropriate. Media was replaced in
this manner every other day until harvest. Mouse NK cells were harvested at day 7, while
human NK cells were harvested at day 4 or day 9, and then sorted to >99% purity for GFP+ NK
cells. For adoptive transfers, YFP+CD27+CD11b- NK cells were sorted from Ncr1-iCre x 15a/161F/F (15a/16-1FKO) or Ncr1-iCre x 15a/16-1WT/WT (Ctrl) mice. GFP+ NK cells were sorted after 45 days of culture, and then additionally expanded for 7-10 days to generate enough GFP+ cells
for adoptive transfer. 5-10x104 GFP+YFP+CD45.2+ donor NK cells were injected into recipient
CD45.1 mice, and allowed to mature. After ten days, spleens were harvested from recipient
mice, and YFP/GFP was used to mark donor cells, which were also stained for NK1.1, CD27,
and CD11b.
Flow cytometry and cell sorting
All flow cytometry was conducted on a Gallios Flow Cytometer (Beckman Coulter), and all cells
were sorted using an iCyte Reflection (iCyt, Champaign, IL) at the Siteman Cancer Center, or
BD FACSAria II (BD Bisociences) at the Washington University Pathology Flow Cytometry and
Fluorescence Activated Cell Sorting Core. Flow cytometry was analyzed using FlowJo
(TreeStar, Ashland, OR).
RISC-Seq
1x106 to 3x106 WT or 155-/- NK cells were sorted, and allowed to recover for two days in
100ng/mL IL-15. The NK cells were then activated with 10ng/mL each of IL-12, IL-15, and IL-18
for 24 hours. RISC-Seq was then performed exactly as described.93
Immunoblots
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1x106 sorted mouse YFP+CD27± or human CD56bright/dim NK cells were lysed in RIPA buffer, run
on an 8-10% SDS-Page Gel (Bio-RAD) and transferred to Immobilon-P (Millipore) membrane.
Immunostaining was performed with Myb @ 1:200, β-actin @ 1:500 overnight at 4 degrees.
Densitometric quantification was performed using ImageJ (NIH).
Statistical analysis
Graphical analysis and statistics were performed with GraphPad Prism 5.0. Student t test, oneway ANOVA, and two-way ANOVA were used as appropriate, with p<0.05 considered
significant. *p<0.05, **p<0.01, ***p<0.001.
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Chapter 3: Global Micro-RNA Deficiency in Natural Killer Cells
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Chapter 3: Preface
miRNAs, especially their particular role in the immune system, were a burgeoning field when
this work began. The first report of ectopic miRNA expression controlling hematopoietic lineage
opened the entire field to exploration.94 However, there are hundreds of miRNAs expressed in
hematopoietic cells, each with its own distinct function. To study the net effect of miRNAs as a
group by assessing individual miRNAs was impossible. In addition, genetic null mutations to the
components of the miRNA processing pathway are embryonic lethal.95
In order to circumvent these issues, a LoxP-flanked conditional Dicer allele was developed.40,45
Thus, the field was opened to the ramifications of total miRNA loss on the development of cells
of the lymphocyte compartment, and a flurry of publications ensued.41–43,96,97 However, the
impact of miRNA loss on NK cells remained unstudied, primarily due to the lack of an available
Cre expressed in NK cells. The only Cre known to be expressed in NK cells, Vav-Cre
(expressed in all hematopoietic cells), when combined with the LoxP-flanked Dicer, was also
lethal at a late embryonic stage (unpublished data). Other models that we tested, including LckCre, were not expressed in NK cells. However, we found that an hCD2-Cre transgene was
selective for NK cells, and was not lethal when combined with the conditional Dicer allele. The
following chapter will discuss our results of global micro-RNA deficiency in NK cells, using the
NK-selective hCD2-Cre. The results of this work were published in The Journal of Immunology
in 2012 and this chapter is adapted from that manuscript.88
While this work was in progress, the Lanier group published their study in which they eliminated
Dicer from NK cells using another Cre expressed in NK cells, a tamoxifen-inducible ER-Cre.70
Though not providing selectivity for the hematopoietic compartment or NK cells in general, they
were the first to publish the striking results of miRNA elimination in NK cells, including a
dramatic loss of NK cells via apoptosis, decreased proliferation, decreased maturation, and
reduced functional responses.
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In contrast, the hCD2-Cre model provides a greater degree of selectivity for NK cells, and
excises the Dicer allele from NK cells uniformly at a very early stage of development. ER-Cre
would be expected to excise Dicer from NK cells at a range of developmental stages, as well as
in non-hematopoietic cells, which may explain the differences in the phenotypes that we
observe. We identified a number of the same phenotypes as the Lanier group, including
apoptosis, decreased proliferation, and decreased maturation; however, hCD2-Cre x Dicer had
increased functional response, indicating that the reduced functional response in the previous
report was caused by cell-extrinsic factors.
Shortly after this paper was published, the Ansel group examined NK cells in the context of
global Eri1 (a protein involved in the degradation of miRNAs) deficiency,98 which resulted in
increased miRNA content in NK cells. In this model, NK cell function was reduced, further
supporting the thesis that the net effect of global miRNA loss is increased cellular death,
decreased proliferation, and increased function. These studies set the stage for further
investigations into the NK cell-intrinsic role of individual miRNAs, including miR-155 and miR15/16.
Shortly after the completion of this work, two distinct NK-specific Cre models were
developed.9,77 Therefore, while this chapter presents data from the first selective deletion of a
gene in NK cells, these improved Cre models will provide a better model of Dicer deletion that
avoids the effects of Dicer on T and B lymphocytes, which could potentially alter NK cell
phenotypes.
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Chapter 3: Abstract
NK cells are innate immune lymphocytes important for early host defense against infectious
pathogens and malignant transformation. MicroRNAs (miRNAs) are small RNA molecules that
regulate a wide variety of cellular processes typically by specific complementary targeting of the
3'UTR of mRNAs. The Dicer1 gene encodes a conserved enzyme essential for miRNA
processing, and Dicer1 deficiency leads to a global defect in miRNA biogenesis. Here, we report
a mouse model of lymphocyte-restricted Dicer1 disruption in order to evaluate the role of
Dicer1-dependent miRNAs in the development and function of NK cells. As expected, Dicer1deficient NK cells had decreased total miRNA content. Further, miRNA-deficient NK cells
exhibited reduced survival, as well as impaired maturation defined by cell surface phenotypic
markers. However, Dicer1-deficient NK cells exhibited enhanced degranulation and interferon
gamma (IFN-γ) production in vitro in response to cytokines, tumor target cells, and activating NK
cell receptor ligation. Moreover, a similar phenotype of increased IFN-γ was evident during acute
MCMV infection in vivo. MiRs-15a/15b/16 were identified as abundant miRNAs in NK cells that
directly target the murine IFN-γ 3’UTR, thereby providing a potential mechanism for enhanced
IFN-γ production. These data suggest that the function of miRNAs in NK cell biology is complex,
with an important role in NK cell development, survival and/or homeostasis, while tempering
peripheral NK cell activation. Further study of individual miRNAs in an NK cell specific fashion
will provide insight into these complex miRNA regulatory effects in NK cell biology.
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Chapter 3: Introduction
Natural killer (NK) cells are an important component of the innate immune system, and have a
key role in early host defense against pathogens and surveillance against malignant
transformation.31,99–101 NK cells develop from precursors arising in the bone marrow (BM), and
complete differentiation and maturation in peripheral lymphoid tissues under the direction of
cytokines and transcription factors,102,103 with IL-15 playing a central role.104,105 During
development from immature precursors, NK cells undergo an education process that results in
tolerance to normal 'self' cells and prevents NK based autoimmunity. This tolerance is achieved
through the expression of a repertoire of germline-encoded activating and inhibitory receptors
that yield signals that are integrated and determine how the NK cell to responds to a target
cell.106–108 NK cells also constitutively express a number of cytokine receptors, and NK
responsiveness is also regulated by cytokines produced by accessory immune cells sensing
pathogens.109 Thus, NK cell development and function in an immune response are distinct from
adaptive T and B lymphocytes.
NK cells function to protect the host through two primary effector pathways –
cytokine/chemokine production and cytotoxicity.110 Mature NK cells may be 'primed' by cytokines
produced by accessory cells sensing pathogens in order to optimize their cytotoxic and
cytokine-secretion potential upon subsequent receptor-based triggering.82,83,111,112 One aspect of
NK cell priming by dendritic cell derived IL-15 includes the rapid translation of perforin and
granzyme B effector proteins.82,111 Secretion of cytokines (e.g. IFN-γ) and chemokines (e.g.
MIP-α, MIP-β, RANTES) by NK cells may directly affect virus-infected or malignant cells,
promote an anti-viral state in adjacent cells, recruit additional immune cells, as well as shape
the subsequent adaptive immune response. In contrast, NK cytotoxicity is triggered primarily by
receptor interaction with a target cell that results in granule exocytosis – the coordinated release
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of perforin and granzymes into a cytotoxic synapse – ultimately inducing apoptotic-like target
cell death.113,114 Lysosomal-associated membrane protein 1 (LAMP-1, CD107a) is retained
within cytotoxic granules and is released on the NK cell surface membrane after ‘triggering’,
providing a marker of recent degranulation.115 While a number of receptors, signaling molecules,
and transcription factors have been identified that regulate NK cell development and activation,
our understanding of the molecular mechanisms regulating these events remains incomplete.
MicroRNAs (miRNAs) are a family of hundreds of small, non-coding RNAs that regulate
numerous cellular functions by targeting sites in the 3'UTR of mRNAs thereby suppressing
translation or causing mRNA degradation.37 MiRNA genes are encoded in the genome,
transcribed as long primary (pri-miRNA) transcripts that are subsequently 'cropped' by the
Drosha/Dgcr8 complex into precursor miRNA (pre-miRNA) that have a characteristic stem loop
structure.38 The pre-miRNA is exported to the cytoplasm where it is further processed by the
Dicer complex (including Dicer1), yielding mature 19-26 nucleotide miRNAs. The mature miRNA
is loaded into the RNA induced silencing complex (RISC), and thereby directs downregulation of
protein levels.47 Genetic disruption of Dicer1 therefore results in decreased or absent levels of a
large number of miRNAs due to interruption in miRNA biogenesis. Previous studies have shown
the requirement of Dicer1 for the processing of miRNAs involved in the maturation and function
of various cell types, including lymphocytes.40–45 In addition, specific miRNAs or miRNA clusters
have

been

implicated

in

B

and

T

cell

development

and

modulate

functional

responses.46 However, only limited information is available on the expression and function of
miRNAs in NK cells, their subsets, and developmental intermediates.
Mature murine NK cells have been shown to express more than 300 mature miRNAs
using a combination of miRNA-SEQ with validation by real-time quantitative PCR and
microarrays.65 Moreover, a subset of these miRNAs are modulated with short-term IL-15
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activation, including miR-223 that was shown to target the murine granzyme B 3'UTR. A number
of miRNAs were expressed in common with other lymphocytes (e.g. miR-181a, miR-21, miR142-3p/5p, miR-16, miR-15b, miR-150, and let-7f), suggesting that these may regulate
lymphocyte development and/or functional programs. A recent study has also identified miR-29
as a contributor to IFN-γ protein regulation in both innate NK cells and adaptive T
cells.72 However, the functional role of the majority of expressed miRNAs in NK cells remains to
be elucidated. What are the ramifications of global miRNA deficiency on developing and mature
NK cells? Answering this question may provide evidence to support the role of miRNAs as
regulators of specific aspects of NK cell development, survival, priming, triggering, or function. A
prior study by Bezman et al. evaluated the phenotype of miRNA deficiency using a global,
inducible estrogen receptor (ER)-Cre model that results in Dicer1 deletion in all cell types in the
mouse after tamoxifen treatment. The authors concluded that miRNA-deficient NK cells have
impaired survival, proliferation, as well as reduced functional capacity as measured by IFN-γ
production and degranulation. These alterations resulted in compromised function during MCMV
infection.70 However, the relative contribution of NK cell intrinsic miRNA deficiency to these
phenotypes was challenging to assess using a global, non-selective miRNA deficiency model
system.
In this study, we employed a lymphocyte-restricted Cre transgenic mouse (hCD2-Cre)
expressed in 30-50% of NK cells,75 coupled with Dicer1 loxP-flanked alleles,40 to generate loss
of Dicer1 in the early stages of NK development. We utilized this model to analyze the role of
Dicer1-dependent miRNAs in the development, maturation, and function of NK cells. We
observed an in vivo developmental and phenotypic maturation defect in miRNA deficient NK
precursors and NK cells. However, despite this defect, Dicer1-deficient NK cells exhibited
enhanced IFN-γ production and degranulation capacity to a number of stimuli ex vivo. Moreover,
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miRNA-deficient NK cells responding to MCMV in vivo exhibited similar enhancement of IFN-γ
production. The miR-15/16 family was identified as potential novel contributors to IFN-γ protein
suppression in NK cells. These findings are consistent with a complex role of miRNAs in NK cell
biology that includes a critical role during NK development/homeostasis, and a separate role for
miRNAs to dampen NK cell functional responses in mature NK cells.
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Chapter 3: Results
hCD2-Cre transgenic / Rosa26-LSL-YFP mice are an NK cell Cre expression model
In order to investigate the role of miRNAs in NK cells, we utilized the lymphoid-restricted hCD2Cre transgenic mouse,75 combined with the Cre reporter model Rosa26-LSL-YFP,76 (CD2Cre/RosaYFP). In this model, all cells that experience Cre-mediated excision at the Rosa26
locus, and all daughter cells, express YFP protein (Figure 3.1A). Using this model, YFP was
found to be expressed in 25-50% of splenic NK cells, and expression was confirmed to be
lymphocyte restricted with >95% of CD3+ T cells and CD19+ B cells, but < 1% of GR-1+ myeloid
cells being YFP+ (Figure 3.1B,C). Furthermore, YFP expression was detected in early NK cell
precursors in the bone marrow as previously defined,12,102 and gradually increased in proportion
throughout development in the bone marrow, with the percentage of YFP+ NK maximal at the
latest stage defined as CD51(integrin αv)- CD117+ (Figure 3.1D,E). In the spleen, YFP+ vs. YFPNK cells exhibited no difference in the expression of Ly49, NKG2D, or NKp46 receptors (Figure
3.2A,B). We observed a modest enrichment in stage II/III NK cells (CD27+CD11b+) (Figure 3.2C)
in YFP+ vs. YFP- NK cells. Since maturation differences could potentially bias the results of
further analyses, we performed all experiments comparing YFP+ NK cells between Dicer1
genotypes, rather than YFP- and YFP+ NK cells in the same mouse. Collectively, these analyses
establish the CD2-Cre/RosaYFP model, whereby YFP+ NK cells in this mouse provide a
mechanism to evaluate the role of Dicer1 alterations in NK cells.
Constitutive Dicer1-deficient NK cells have reduced miRNA content
The CD2-Cre/RosaYFP mice were further crossed to mice with various genotypes of loxPflanked Dicer1 thereby generating Dicer1fl/fl, Dicer1fl/wt, or Dicer1wt/wt mice. Since Cre excision at
the Rosa26 locus occurred in only a proportion of mature NK cells, we first evaluated loxPflanked Dicer1 excision status in YFP+ and YFP- NK cells. Utilizing qRT-PCR to identify excised
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versus WT Dicer1 mRNA (Figure 3.3A), we compared the levels of Dicer1 excision in the
Dicer1fl/fl mice to the Dicer1fl/wt mice. Surprisingly, we found that the YFP+ NK cells in both
genotypes had comparable degrees of excision detected by this assay (Figure 3.3B). Complete
excision in the Dicer1fl/fl NK cells is expected to result in no detection with the internal primers
and maximal detection with the external primers. Therefore, this result suggested that NK cells
in the Dicer1fl/fl mice that have completely excised Dicer1 have compromised survival, and those
NK cells that have excised only one, or neither, Dicer1 allele preferentially survive. To
investigate Dicer1 excision at the level of an individual cell rather than a bulk population, we
performed single cell PCR on sorted YFP+ and YFP- NK cells (Figure 3.3C,D), and found that a
substantial proportion (26%) of YFP+ NK cells in Dicer1fl/fl mice had not excised either allele of
Dicer1, consistent with the qRT-PCR results. Furthermore, by both assays we found that Dicer1
floxed alleles were also excised in a small fraction of YFP- NK cells (Figure 3.3B,C), possibly
due to loss of YFP in Dicer1fl/fl cells undergoing apoptosis or imperfect Rosa26-YFP excision.
This therefore provided a second rationale for comparing YFP+ NK cells between Dicer1
genotypes in order to eliminate this additional potential confounder.
To confirm the functional impact of excision of Dicer1 in the Dicer1fl/fl and Dicer1fl/wt mice,
we next determined the expression of mature miRNAs within various Dicer1 genotypes. We
examined YFP+ NK cells for mature miRNA expression by Nanostring miRNA assays (Figure
3.3E,F), and found that there was a consistent loss of miRNA content in the Dicer1fl/fl and
Dicer1fl/wt NK cells. We further confirmed this loss for three miRNAs representing a range of
expression in NK cells (miR-16, miR-21, and miR-30b)65 via quantitative real time RT-qPCR
(Figure 3.3G). Because miRNA expression in Dicer1fl/fl NK cells was reduced but not absent,
these data are also consistent with a model in which Dicer1∆/∆ NK cells have compromised
survival due to complete loss of miRNAs, and are not viable. This is also consistent with the
incomplete excision seen in the single cell PCR assay. Taken together, these data suggest that
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examining both Dicer1fl/wt and Dicer1fl/fl YFP+ NK cells will be useful to elucidate the phenotype
of miRNA-deficient NK cells.
MiRNA-deficient NK cells exhibit defects in survival and maturation
To evaluate effects of Dicer1-deficiency on NK cells in vivo, we first analyzed the percentage of
YFP+ NK cells in the spleen, liver, blood, and bone marrow of CD2-Cre/RosaYFP mice with
various Dicer1 genotypes. We observed a reduced proportion of YFP+ NK cells in Dicer1fl/fl mice
(spleen: 14.42 ± 3.66%) compared to Dicer1fl/wt (spleen: 35.44 ± 7.18%) and Dicer1wt/wt mice
(spleen: 35.74 ± 7.68%) (Figure 3.4A), further indicating a loss of YFP+ NK cells in the Dicer1fl/fl
mice. In addition, while the absolute number of total NK cells was equivalent in all three
genotypes (Figure 3.4B), there was a significant reduction in the splenic YFP+ NK cell
compartment in Dicer1fl/fl mice. While the bone marrow showed a similar pattern, the liver and
blood showed no significant difference in the numbers of total NK and YFP+ NK cells for all
three genotypes (Figure 3.5D).
Given the remarkable loss of YFP+ NK cells in the spleen of Dicer1fl/fl mice, we examined
whether YFP+ NK loss was associated with peripheral maturation stage. NK cell maturation has
been defined in the periphery of mice using co-expression of CD27 and CD11b surface
markers,11,12 and we evaluated YFP expression in these NK cell maturation subsets (Figure
3.4C). There was a defect in Dicer1fl/fl NK cells beginning at Stage II (CD27highCD11blow) and
continuing through Stage IV (CD27lowCD11bhigh), while a defect in the Dicer1fl/wt YFP+ NK cells
was only evident at Stage IV. This supports a significant, but less severe, effect of miRNA loss
on NK cell maturation and/or survival in the Dicer1fl/wt YFP+ NK cells as compared to the
Dicer1fl/fl YFP+ NK cells. Thus, Dicer1 loss in NK cells leads to a lower absolute number and
percentage of YFP+ NK cells, an effect which is cell-intrinsic and evident at early stages of
maturation for Dicer1fl/fl mice, and late stages for Dicer1fl/wt mice.
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Dicer-deficient NK cells exhibit reduced IL-15-induced survival and proliferation
We next investigated whether the defects of Dicer1-deficient NK cells could be rescued in vitro
by IL-15, an essential NK cell survival factor. To examine the survival of YFP+ NK cells in vitro,
bulk splenocytes were cultured in K10 medium with varying concentrations of rmIL-15. After 24,
48, and 72 hours in medium only (without IL-15) there was a marked decrease in the absolute
number of YFP+ NK cells in all Dicer1 genotypes as expected, although a significantly greater
survival of the Dicer1wt/wt compared to either the Dicer1fl/wt or Dicer1fl/fl at 24 hours (Figure 3.6A).
With low dose (5 ng/mL) IL-15, there was prolonged survival of the YFP+ NK cells in the
Dicer1fl/wt and Dicer1wt/wt mice, but this effect was significantly decreased in the Dicer1fl/fl
mice. With high dose (100 ng/mL) IL-15 a similar phenotype was observed; however, high dose
IL-15 partially rescued Dicer1fl/fl YFP+ NK cell numbers, compared to low dose IL-15. These
results were also confirmed using sorted YFP+ NK cells (Figure 3.7A). These results indicate
that Dicer1-deficient NK cells have a cell-intrinsic defect in cell survival which is partially rescued
with high doses of IL-15.
As a potential mechanism responsible for the IL-15-induced survival defect, we
investigated IL-15R protein expression (CD122, CD132), as well as downstream phosphoSTAT5 (Figure 3.7B). We found no decrease in the CD122 or CD132 positive percentage (or
MFI) of Dicer1fl/fl, compared to Dicer1fl/wt or Dicer1wt/wt, YFP+ NK cells. Similarly, there was no
decrease in phospho-STAT5 after short-term IL-15 stimulation. In fact, we observed a modest
increase in CD132 expression (96 ± 0.6% vs. 91 ± 1.9%, p<0.05) and IL-15-induced phosphoSTAT5 (91 ± 1.1% vs. 84 ± 0.7%, p<0.001) in Dicer1fl/fl compared to Dicer1wt/wt YFP+ NK
cells. Thus, it is unlikely that reduced IL-15R expression or pSTAT5 signals are responsible for
the observed survival defect.
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We next evaluated the ability of IL-15 and IL-18 to induce proliferation in NK cells from
these mice. Splenic NK cells were labeled with CellTrace Violet (a CFSE-analogue) and
cultured in 5 ng/mL IL-15, 100 ng/mL IL-15, or 100 ng/mL IL-15 + 10 ng/mL IL-18 to induce
proliferation (Figure 3.6B). After 3 days, Dicer1fl/fl YFP+ NK cells had reduced proliferation in 100
ng/mL IL-15 + 10 ng/mL IL-18 (p<0.05) compared to Dicer1wt/wt NK cells, as measured by dye
dilution with cell division. After 5 days, Dicer1fl/fl YFP+ NK cells had reduced proliferation in both
100ng/mL IL-15 (p<0.01) and 100ng/mL IL-15 + 10ng/mL IL-18 (p<0.01) compared to Dicer1wt/wt
NK cells. There was normal proliferation in the Dicer1fl/wt NK cells. Therefore, Dicer1-deficient
NK cells exhibit an in vitro survival and proliferative defect.
Dicer-deficient NK cells exhibit enhanced degranulation and IFN-γ production ex vivo
We evaluated the functional capacity of Dicer1-deficient NK cells in vitro. Splenocytes from
these mice were cultured in either K10 medium alone or stimulated with YAC-1 cells (NK cell
stimulatory cell line); 10 ng/mL IL-12 + 100 ng/mL IL-15, an IFN-γ inducing cytokine stimulus; or
plate-bound anti-NK1.1 (PK136) to generate a potent activating NK cell receptor signal (Figure
3.8A). After 7 hours of culture both CD107a (a marker of degranulation) (Figure 3.8B) and IFN-γ
production (Figure 3.8C) were assessed by flow cytometry. Notably, the Dicer1fl/fl mice had a
significantly higher percentage of CD107a+ (degranulated) YFP+ cells when cultured ex vivo,
even in the absence of stimulation, or when stimulated via cytokines, NK cell receptor ligation,
or tumor cell interaction. In addition, the Dicer1fl/wt YFP+ NK cells also had significantly higher
degranulation than the Dicer1wt/wt NK cells in the IL-12+IL-15 and anti-NK1.1 cross linking
conditions, and a similar trend that did not reach statistical significance for medium or YAC-1 coculture. IFN-γ responses were similarly enhanced in Dicer1fl/fl YFP+ NK cells in medium, YAC-1
co-culture and NK1.1 ligation, compared to Dicer1wt/wt NK cells. In the setting of IL-12 + IL-15
stimulation, there was a significant increase in IFN-γ in Dicer1fl/wt compared to Dicer1wt/wt and
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Dicer1fl/fl NK cells; however, the Dicer1fl/fl did not exhibit enhanced IFN-γ with this cytokine
combination. In addition, to confirm that this phenotype was cell-intrinsic, sorted YFP+ NK cells
were cultured in media alone or with plate-bound anti-NK1.1 (Figure 3.7C). Sorted YFP+
Dicer1fl/fl cells stimulated with anti-NK1.1 produced significantly more IFN-γthan their YFP+
Dicer1wt/wt counterparts (93 ± 7.3 v. 39 ± 18, p<0.05). Collectively, these data show that miRNAdeficient NK cells have a cell-intrinsic enhanced capacity to produce IFN-γ and degranulate in
response to multiple stimuli in vitro.
We also investigated the impact of maturation stage defined by CD27/CD11b on
degranulation (CD107a), and observed that stage II-III NK cells in the Dicer1fl/fl mice were
primarily responsible for the enhanced degranulation (Figure 3.9A). Prior studies have shown
that stage III NK cells exhibit a higher degranulation capacity compared to the more mature
stage IV subset, which may allow increased degranulation due to miRNA defects in these cells
to be more readily apparent.11,12 In addition, this effect was not due to altered Ly49/NKG2D
receptor expression (Figure 3.9B). Thus, neither maturation stage skewing nor Ly49/NKG2D
expression changes seem responsible for the observed phenotype. Granzyme B protein levels
were found to be variable in NK cells from these mice, with a trend toward increased expression
in Dicer1fl/fl (Figure 3.9C). This implies that miRNA loss, even the smaller decrement in Dicer1fl/wt
mice, may control the activation threshold of NK cells.
Dicer1-deficient NK cells exhibit enhanced IFN-γ production in vivo during MCMV infection

To evaluate the impact of miRNA-deficiency in NK cells during a physiologic in vivo response,
we infected Dicer1fl/fl, Dicer1fl/wt, and Dicer1wt/wt with 5x104 PFU of MCMV and evaluated IFN-γ
production 36 hours post-infection, the expected peak IFN-γ time point. Consistent with the in
vitro results, splenic YFP+ NK cells from Dicer1fl/fl mice had significantly higher IFN-γ protein
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production compared to Dicer1wt/wt mice (Figure 3.9A,B). Further, Dicer1fl/wt mice demonstrated
an intermediate phenotype, with IFN-γ production between Dicer1fl/fl and Dicer1wt/wt. These data
suggest that miRNA-deficient NK cells have an enhanced ability to produce IFN-γ in vivo during
an ongoing anti-viral response.
The miR-15/16 family specifically targets the IFN-γ 3’ UTR
As IFN-γ production was significantly increased in miRNA-deficient NK cells both in vitro and in
vivo, we evaluated the role of individual miRNAs for their potential to directly target IFN-γ protein
production via binding to the murine IFN-γ 3’UTR. A number of miRNAs are predicted
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algorithms to bind to the murine IFN-γ 3'UTR, including miRs-15a/15b/16, a closely related
family of microRNAs (Figure 3.10A). Culture of sorted NK cells for 7 hours with stimuli that
induce IFN-γ protein expression, 100 ng/mL IL-15 + 10 ng/mL IL-12 or plate-bound anti-NK1.1,
resulted in a significant reduction of miR-15b in both conditions, and a significant reduction in
miR-15a and miR-16 in the 12+15 condition (Figure 3.10B). These miRNAs are among the most
highly expressed miRNAs in IFN-γ producing lymphocytes (Figure 3.10C), and have decreased
expression in Dicer1fl/fl and Dicer1fl/wt mice (Figure 3.3E). We therefore evaluated the miR-15/16
family, along with a number of candidates using in vitro over-expression of individual miRNAs
with concurrent 3'UTR luciferase 'sensor plasmid' as a readout of targeting (Supplemental
Figure 4A). Some miRNAs, such as miR-27a and miR-29a, were found to repress the empty
vector, and were discarded due to a lack of specificity. The miR15/16 family was not found to
target the empty psiCheck2 vector (Figure 3.11A), but was strongly predicted to target the IFN-γ
3’ UTR in two sites (Figure 3.10D). In co-transfection assays in which Renilla luciferase is fused
to the 3’ UTR of IFN-γ, overexpression of miR-15a/16-1 or miR-15b/16-2 in 293T cells
(Supplemental Figure 4B) dramatically decreased the Renilla signal compared to negative
controls (GFP only 'empty' vector or overexpression of an irrelevant miRNA) (Figure 3.10E).
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This indicates that miRs-15a/15b/16 regulate the IFN-γ 3’UTR. To interrogate the specificity of
the IFN-γ 3’ UTR repression, we specifically mutated the top predicted site (IFN-γmut-1) or the
top two (IFN-γmut-1+2) predicted sites (Figure 3.1D). This resulted in a sequential and
substantial loss and abrogation of IFN-γ 3’UTR repression by miR15a/15b/16, indicating that the
targeting was direct. Thus, these biochemical results, plus the expression pattern in
resting/stimulated WT NK cells and Dicer1fl/fl vs. Dicer1wt/wt mice, are consistent with miR-15/16
targeting of the 3'UTR as a possible mechanism for increased IFN-γ production in our model.
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Chapter 3: Discussion
In this study we utilized a combination of genetic mouse models to achieve 'selective' miRNA
deficiency in NK cells, which are identifiable due to their expression of YFP. Based upon the
Rosa26-LSL-YFP reporter allele, Cre expression and Dicer1 excision consistently occurred
early in NK cell development, and persisted in mature peripheral NK cells. This model
demonstrated that Dicer1-dependent miRNAs play a role in NK cell development, survival, and
proliferation - when miRNAs are globally decreased, NK cell development and maturation are
impaired. These results suggest that specific miRNAs or groups of miRNAs are important
intrinsic regulators of NK cell development and homeostasis. However, our results also revealed
that miRNA-deficient NK cells had enhanced functionality, which included increased IFN-γ
production and degranulation (as a surrogate for cytotoxicity) in vitro, and enhanced IFN-γ
responses in vivo during MCMV infection. This phenotype indicates that miRNAs also play a
role in dampening NK cell responses in mature peripheral NK cells. Indeed, we identified a
family of related miRNAs, miR-15a/15b/16, that are decreased in Dicer1-deficient mice and
during NK cell activation, and directly target the IFN-γ 3'UTR. Thus, miRNA regulation of NK cell
molecular programs is complex, with effects in development and homeostasis, as well as
regulating NK cell functional responses.
Limited studies have been performed to date evaluating the expression and significance
of miRNAs in NK cell biology. We have previously defined the expression of miRNAs in resting
mature murine NK cells and following IL-15 activation using multiple profiling platforms,
including miRNA-SEQ, and identified novel miRNAs in NK cells.65 Consistent with our current
hypothesis regarding IFN-γ regulation, miRs-15a/15b/16 were highly expressed in resting NK
cells. In the prior study, miR-223 was also identified as a potential direct regulator of another NK
cell effector molecule, granzyme B, in resting NK cells. In our current study, granzyme B protein
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levels had a high degree of variability, with a trend toward higher granzyme B protein in Dicer1fl/fl
NK cells, compared with Dicer1fl/wt or Dicer1wt/wt. Since our Dicer1-deficiency model results in the
decrease of a large number of miRNAs simultaneously, there may be indirect effects on other
pathways important for granzyme B expression in NK cells, or it may disrupt miRNAs that both
positively and negatively regulate granzyme B expression. Current experiments utilizing miR223-/- mice,117 are underway to further evaluate the regulation of NK cell function by miR-223.
Bezman et al. recently reported the phenotype of NK cells in the context of drug-induced
Dicer1 or Dgcr8 (a critical component of the Drosha complex) loss, utilizing an estrogen
receptor (ER)-Cre model to excise Dicer1fl/fl or Dgcr8fl/fl alleles.70 Such an approach reduces
miRNAs in all cells of the mouse (including NK cells) after 5 days of tamoxifen treatment. This
study identified a phenotype similar to our model for miRNA-deficiency in regards to NK cell
survival; however, there were a number of phenotypic differences that warrant discussion in the
context of the disparate models. The hCD2-Cre model in our study reduces miRNA expression
in NK cells from a uniform point during NK cell development, with consistent loss of miRNAs in
mature NK cells. In contrast, the ER-Cre model results in a 'window' of Cre mediated excision in
both mature NK cells and presumably their precursors following tamoxifen treatment, and thus
provides a potentially heterogeneous NK cell population with regards to the timing of Dicer1 or
Dgcr8 loss during NK cell development and maturation. In addition, ER-Cre eliminates Dicer1
and Dgcr8 in all mouse cells providing no selectivity for NK cells, and therefore using this
approach it may be challenging to differentiate the effects of NK cell intrinsic vs. extrinsic miRNA
deficiency. These differences between the model systems may be responsible for the
contrasting phenotypes we are reporting for mature NK cell function. The ER-Cre model
described a 'hypofunctional' NK cell phenotype with impaired IFN-γ production and
degranulation in response to activating NK cell receptors in vitro - the opposite of the phenotype
we observed using the hCD2-Cre model. In addition, the authors report increased NKG2D
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receptor expression in miRNA-deficient NK cells, which we did not observe in the hCD2-Cre
model. In the setting of MCMV infection, the ER-Cre approach identified no change in IFN-γ
production by splenic NK cells during MCMV infection. However, in the hCD2-Cre model there
was a clear statistically significant increase in IFN-γ protein in splenic NK cells 36 hours postinfection. Similar to our phenotype with hCD2-Cre driving Dicer1-loss in NK cells, CD8+ T cell
responses in Dicer1-/- mice achieved by a distal Lck-Cre identified enhanced activation with
faster kinetics in miRNA-deficient CD8+ T cells.118 Recently, Eckelhart, et. al. and NarniMancinelli, et. al. have independently reported NK cell-specific NKp46-Cre mice.77,119 Future
studies utilizing these models that direct Cre expression only in NK cells or NK cell precursors
will provide additional information on the functional ramifications of miRNA biogenesis or
specific miRNAs in vivo.
The data presented support a role for miRNAs in the appropriate survival, maturation,
and proliferation of NK cells. As the turnover of Dicer1 protein and miRNAs is rapid,42–45 and NK
cell maturation takes weeks,120 Dicer1 protein and therefore Dicer1-dependent small RNAs are
likely reduced at an early stage of NK development. By using a model in which Dicer1 excision
occurs contemporaneously and at an early stage of NK cell development, we could analyze the
role of Dicer1 in the survival and maturation of NK cells. By analyzing various organs, we
observed that Dicer1fl/fl NK cells failed to reach a defined stage of peripheral NK cell
development: the CD27+CD11blow stage, which is associated with cellular proliferation,12
consistent with the crucial function of miRNAs in cell division.121 In contrast, Dicer1fl/wt NK cells
were underrepresented in the final stages of NK maturation, possibly indicating a failure in
proper senescence,122,123 and consistent with the intermediate level of miRNAs in these cells as
analyzed by Nanostring. As the numbers of YFP+ NK cells were only significantly decreased in
the spleen and bone marrow, we cannot formally rule out that these alterations may be due to a
homing defect of the Dicer1fl/fl NK cells. However, this seems less likely given the defect in the
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NK YFP+ percentage of all peripheral organs. Furthermore, there was a significant decrease in
the ability of miRNA-deficient NK cells to survive in IL-15-containing media, which was not
explained by reduced IL-15R protein expression or signals via phosphoSTAT5. MiRNAs
previously reported to have a role in regulating development and proliferation, miR-150,124 miR16,125 and miR-21,126 are highly expressed in NK cells, and are likely candidates to be involved
in the repression of genes required for proper development and proliferation in maturing NK
cells.
NK cell activation involves an intricate relationship between activating and inhibitory
signaling, with an activation threshold determined by a variety of interactions, many of which
have yet to be fully understood.127 Previous reports have shown a specific role for miR-181a in
tuning the sensitivity of T cells,128,129 by targeting the phosphatases PTPN22 and SHP-2. The
increased NK cell functionality in our hCD2-Cre model implies the net effect of reduced Dicer1dependent miRNAs in NK cells is loss of activating signal repression, possibly via a loss of
targeting of DAP12, other ITAM-containing receptors or their downstream signaling molecules,
as well as cytokine receptor signaling pathways. As NK cell activation can be extremely
sensitive to minute changes in activating and inhibitory receptor levels,130 it is a prime candidate
for miRNA-based “fine tuning”. It is likely that because both degranulation and IFN-γ production
are increased in the Dicer1fl/fl NK cells, molecule(s) upstream of both degranulation and cytokine
production may be targets of miRNAs. The impact of miRNAs on the signals that ultimately are
integrated from activating and inhibitory cell surface molecules are a potential mechanism
contributing to whether an NK cell responds once triggered.
IFN-γ regulation is multi-faceted, and includes control of gene transcription as well as
post-transcriptional events.131 We identified loss of miR-15/16 family miRNAs as potential
players responsible for the increased IFN-γ production in the hCD2-Cre/RosaYFP Dicer1fl/fl
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mice. These related miRNAs are highly expressed in resting NK cells, target the 3’ UTR of
murine IFN-γ, and are decreased in Dicer1fl/fl and Dicer1fl/wt NK cells. It has been previously
suggested that IFN-γ is regulated in humans by a psuedoknot element in its 5’ UTR,132 and by
miR-29.72,133 While we also initially identified miR-29 as a potential IFN-γ regulator using in silico
algorithms, it did not target the mouse 3’UTR in our luciferase-based assays. Consistent with
our targeting data, miR-15/16 has a much higher relative expression than miR-29 in NK cells,
and is highly expressed in NK and T cells, providing further biological rationale for the regulation
of IFN-γ. Moreover, the 3’ UTR of IFN-γ is conserved between human and mouse, and miR15/16 is predicted to target human IFN-γ, indicating a potential conserved mechanism between
species. The miR-15/16 family is known to be highly expressed in lymphocytes as defined by
miRNA-SEQ,65 suggesting that it has an integral role in lymphocyte development and/or
function. Additionally, the miR-15/16 loci has been implicated in a variety of cellular roles in
lymphocytes.66,67,134 This study’s finding that miR15/16 targets IFN-γ, a crucial immune response
molecule, provides further evidence for miR15’s vital role in the immune response. Future
studies will involve specifically targeting miR-15/16 family members in NK cells.
MiRNAs have been found to have a role in nearly all cell types, and to exert their
regulation on a wide variety of cellular functions. In this study, we identify the role of miRNAs in
modulating the proliferation, survival, and the essential functions of NK cells. MiRNA-deficient
NK cells have decreased survival and proliferation, but increased degranulation and IFN-γ
production, implying a central role for miRNAs in the control of physiologic NK cell
responses. The role of miRNAs in dampening NK cell function may be found to have a broad
impact on the fields of autoimmunity, viral defense, tumor immunotherapy, and hematopoietic
stem cell transplantation, in which roles for NK cells are well established.70 Future studies, which
will require more subtle manipulations of individual miRNAs or miRNA clusters, will further
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define the mechanism by which miRNAs control the development and activation threshold of NK
cells.
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Figure 3.1
hCD2-Cre transgenic Cre expression is lymphocyte-specific, present in NK cells at early
stages of NK development, and maturing NK cells are YFP positive early in maturation.
(A) Schema of mouse genotypes utilized in this study illustrating dicerf/f, dicerf/wt, and dicerwt/wt
groups with hCD2-Cre expression marked by YFP expression from the Rosa26 locus. LoxP
sites are indicated with triangles, exons are indicated by boxes.
(B-C) Representative flow histograms (B) and summary data (C) demonstrating the YFP
expression of lymphocyte subsets from the spleen in CD2-Cre/RosaYFP mice. Data are the
percentage of YFP positivity in each cell type, including NK (NK1.1+CD3-), T (CD3+NK1.1-),
NK-T (NK1.1+CD3+), B (CD19+CD3-NK1.1-), and myeloid (Gr-1+) cells and represent at least 3
independent experiments.
(D-E) Representative histograms (D) and summary data (E) of the percentage of YFP positivity
in NK cell developmental intermediates in the bone marrow as defined by Kim et al.102 with
stage definitions by phenotype listed below each YFP histogram (representative of 2
independent experiments). Significance was calculated using one-way ANOVA. *p<0.05,
**p<0.01,***p<0.001.
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Figure 3.2
YFP+ and YFP- NK cells are phenotypically similar; however, YFP+ NK cells are more
immature than YFP- NK cells, an effect which is exaggerated in the Dicerfl/fl mice.
(A) Flow plots of characteristic NK markers on YFP+ NK cells (Black) or YFP- NK cells (Gray).
Shaded gray represents isotype control. Data are representative of 3 experiments with 2 mice
each.
(B) Summary data for Ly49 expression on YFP+ and YFP- NK cells in Dicer1fl/fl and Dicer1fl/wt
mice.
(C) Left: Representative flow cytometry plots for YFP+ and YFP- NK cells from each Dicer1
genotype. Right: Ratio of YFP+ to YFP- at each genotype. Immature NK cells (Stage I, II, III) are
over-represented in the YFP+ NK population, while mature NK cells (Stage IV) are underrepresented.
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Figure 3.3

hCD2-Cre transgene expression in NK cells results in Dicer1 excision and loss of mature
miRNA expression.

(A) Representation of the genomic loxP (triangles)-flanked Dicer1 allele exons (boxes). Primers
designed to amplify intact Dicer1 (black) or excised Dicer1 (gray) from cDNA are shown.
(B) Real-time RT-qPCR analysis of intact Dicer1 mRNA (left, black bars) or excised Dicer1
mRNA (right, white bars) in various Dicer1 genotypes of sorted YFP+ NK cells. For qPCR all
samples were normalized to 18s rRNA using the ∆∆CT method, and then compared to the level
of Dicer1 mRNA in WT NK cells. Data shown are the mean ± SEM of 2 experiments.
(C) MiRNA expression in YFP+ Dicer1fl/fl, Dicer1fl/wt, Dicer1wt/wt NK cells measured by Nanostring.
Absolute expression profiles of the top 15 miRNAs expressed in Dicer1wt/wt as analyzed by
Nanostring

showing

decreased

miRNA

expression

in

Dicer1-deficient

NK

cells.

(D) Summary of miRNA expression changes in Dicer1fl/fl, Dicer1fl/wt, and Dicerwt/wt YFP+ NK Cells.
The geometric mean of Nanostring count groups (>5000, 1000-5000, 100-1000) was compared
between Dicer1 genotypes.
(E) Confirmation of selected miRNA expression utilizing qRT-PCR of miR-16, miR-21, and miR30b. Data shown are the mean ± SEM of 3 independent experiments. Significance was
calculated using Student’s t-test. *p<0.05, **p<0.01, ***p<0.001.
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Figure 3.4

MiRNA-deficient NK cells exhibit an in vivo survival defect. Mononuclear cells were isolated
from spleen, liver, blood, and BM and NK cells (CD45+NK1.1+ NKp46+CD3-) and analyzed for
YFP expression.

(A) Percent YFP positive NK cells in indicated tissues for each genotype.

(B) Total viable cells were enumerated, the percentage of YFP± NK cells was analyzed by flow
cytometry, and absolute total NK and YFP+ NK cell numbers were calculated. Significance in (AB) was defined using 1-way ANOVA with a Neuman-Keuls post-test.

(C) NK cells were further analyzed for CD27 and CD11b expression, and the absolute number
of cells was calculated as above for maturation stages I (CD27-CD11b-), II (CD27+CD11b-), III
(CD27+CD11b+), and IV (CD27-CD11b+) as described.42–45 Significance was calculated using
2-way ANOVA and is presented as Dicer1fl/fl (gray) or Dicer1fl/wt (black) v. Dicer1wt/wt. Data shown
are the mean ± SEM of 5 experiments (A-B) or 3 experiments (C) with 2-6 mice of each
genotype per experiment. *p<0.05, **p<0.01, ***p<0.001.
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Figure 3.5
The increased degranulation of the Dicerfl/fl mice is due to an increase in degranulation
by the Stage II-III NK Population, but not due to altered Ly49 Receptors.
(A) The same assay as in Figure 5 was analyzed for the degranulation of CD27+ (Stage II-III) or
CD27lo (Stage IV) NK cells. Cells were gated on CD3-NK1.1+NKp46+YFP+, and the percentage
of degranulating cells was measured.
(B) CD3- NK1.1+ NKp46+YFP+ NK cells were measured for their Ly49 content.
(C) Bulk splenocytes were cultured for 48 or 72 hours in 5ng/mL (Low) or 100ng/mL (High) IL-15
and Granzyme B was measured by intracellular flow. Shown are the mean ± SEM of two
experiments with 2-3 (A), or 1-4 (B-C) mice per genotype.
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Figure 3.6
MiRNA-deficient NK cells exhibit defective survival and proliferation in vitro.
(A) Splenocytes from CD2-Cre/RosaYFP reporter mice and the indicated Dicer1 genotypes
were plated in 24 well plates in K10 medium supplemented with 0, 5, or 100 ng/mL of rmIL15. The percentage and absolute number of YFP+ NK cells was determined by flow cytometry
using counting beads after 2, 24, 48, and 72 hours of culture. Data shown is the mean ± SEM
YFP+ NK cell number normalized to the 2-hour time-point from 3 independent experiments.
Significance was calculated using 2-way ANOVA and is presented as Dicer1fl/fl (gray) or
Dicer1fl/wt (black) v. Dicer1wt/wt. *p<0.05, **p<0.01, ***p<0.001.
(B) Splenocytes from CD2-Cre/RosaYFP reporter mice and the indicated Dicer1 genotypes
were labeled with CellTrace Violet and plated in K10 medium supplemented with 5 ng/mL (low
15), 100 ng/mL (high IL-15) rmIL-15, or 100 ng/mL rmIL-15 plus 10 ng/mL rmIL-18
(15+18). Cells were harvested after 3 or 5 days and YFP+ NK cells were analyzed for
proliferation indicated by dilution of CellTrace Violet dye.
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Figure 3.7
Total number of NK and YFP+ NK cells in the bone marrow, blood, and liver, and at each
maturation stage in those organs.
(A-B) The total # of YFP+ NK cells (A) at each developmental stage (B) was calculated by trypan
blue counting and flow cytometry percentages as in Figure 3.4. Presented are the mean ± SEM
of 2 experiments with 2 mice per experiment. Significance was calculated using a one-way
ANOVA with Neuman-Keuls post-test (A) or two-way ANOVA of f/f v. wt/wt (red) or f/wt v. wt/wt
(green) (B). p<0.05, **p<0.01, ***p<0.001.
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Figure 3.8
miRNA-deficient NK cells have increased functional capacity defined by in vitro
degranulation and IFN-γγ production..
Splenocytes were cultured for 7h in K10 medium only, or stimulated with YAC-1 tumor cells, IL12+IL-15, or anti-NK1.1 ligations (plate bound PK136).
(A) Example flow cytometry gating scheme that identifies NK1.1+ NKp46+CD3-YFP+ NK cells
expressing cell surface CD107a or intracellular IFN-γ protein in Dicer1wt/wt splenocytes.
(B-C) Summary data of the percent positive NK cells for CD107a (B) or IFN-γ (C) expression
after 7h with the indicated stimulus. The mean ± SEM of 5 independent experiments is shown
expressed as the percent maximal expression within each experiment to account for expected
inter-assay variability. Significance was calculated using 1-way ANOVA. *p<0.05, **p<0.01,
***p<0.001.
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Figure 3.9

miRNA-deficient NK cells exhibit enhanced IFN-γγ production and degranulation in
response to MCMV in vivo..

(A-B) Mice were infected IP with 5x104 PFU of MCMV, and spleens were analyzed for IFN-γ
expression by flow cytometry after 36 hours. (A) Representative flow cytometry of YFP
expression and IFN-γ staining, previously gated on CD45+NK1.1+NKp46+CD3- lymphocytes. (B)
Summary data of IFN-γ staining. Data shown are the mean ± SEM of two independent
experiments. Significance was calculated using 1-way ANOVA. *p<0.05, **p<0.01, ***p<0.001.
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Figure 3.10
The miR-15/16 family is highly expressed in NK cells, decreases upon cytokine
activation, and directly represses the murine IFN-γγ 3'UTR.
(A) Schematic of the relationship of the miR-15/16 family members. (|) indicates a base pair
match, whereas (x) indicates base pair differences. Underlined nucleotides indicate the miRNA
“seed” sequence.
(B) RT-qPCR of sorted WT NK cells activated at baseline (black) or activated for 7 hours (white)
in 100ng/mL IL-15 + 10ng/mL IL-12 (left) or with plate-bound PK136 (right).
(C) Nanostring miRNA expression analysis comparing the levels of miR-15/16 in sorted NK,
CD4+ T, and CD8+ T lymphocytes illustrating that miR-15/16 is abundant in IFN-γ producing
cells.
(D) Schematic of two separate predicted mir-15/16 binding sites within the IFN-γ 3'UTR, with
Watson-Crick (|) and wobble (:) base pairing indicated. In the mutated IFN-γ 3'UTR sequence,
“x” indicates base pair location altered to disrupt predicted miR-15/16 binding. Nucleotide
numbering indicates position from the 5' end of the IFN-γ 3’ UTR.
(E) 293T cells were co-transfected with the psiCheck2-IFN-γ 3’UTR sensor plasmid and a
pMND vector over-expressing GFP and either miR-15a/16-1 or miR-15b/16-2. Compared to a
GFP-only expression vector, or irrelevant miRNA (miR-21, not shown), mmu-miR-15a/16-1 (left)
and mmu-miR-15b/16-2 (right) repress translation via the IFN-γ 3’ UTR. This repression is
abrogated when both binding sites are mutated, indicating that miR-15/16 repression is
specific. Data shown are the mean ± SEM of at least 2 (B,C) or 3 (E) independent experiments.
Significance was calculated using 1-way ANOVA. *p<0.05, **p<0.01, ***p<0.001.
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Figure 3.11
pSICheck-2 targeting by a variety of microRNAs predicted to target IFN−γ
−γ,
−γ and their
relative overexpression in 293T cells
(A) Summary data for the effect of various microRNAs on the 3’UTR of IFN−γ as measured by
overexpression of each microRNA concurrently with psiCheck-2 vector fused to either no 3’
UTR (left) or with the 3’ UTR of IFN−γ (right).
(B) Specific overexpression of either miR-15a (left) or miR-15b (right) in miR15a/16-1 or
miR15a/16-2–transfected HEK293T cells. Mean overexpression for all tested miRNAs was
15.28 ± 8.12-fold. Data are presented as mean ± SEM of at least two independent experiments.

62

A
No 3' UTR

IFNg 3'UTR
150
Normalized
Renilla/Firefly

100

50

50

29
C

29
A

27
A

Em
15 pt
A y
/
15 16B 1
/1
62

29
C

29
A

27
A

0

21
26
A

Em
15 pt
A y
/
15 16B 1
/1
62

0
Overexpressed miRNA:

100

21
26
A

Normalized
Renilla/Firefly

150

B
mmu-mir-15b

mmu-mir-15a
50

Fold Overexpression

Fold Overexpression

50
40
30
20
10

40
30
20
10
0

0
pSICheck2
MND

Mock Empty Empty Empty IFNg IFNg IFNg mut1 mut1 mut1
Mock Empty 15A 15B Empty 15A 15B Empty 15A 15B

pSICheck2
MND

63

Mock Empty Empty Empty IFNg IFNg IFNg mut1 mut1 mut1
Mock Empty 15A 15B Empty 15A 15B Empty 15A 15B

Chapter 4: MicroRNA-155 Tunes Both the Threshold and Extent of NK Cell Activation via
Targeting of Multiple Signaling Pathways
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Chapter 4: Preface
The findings in this chapter were a natural outgrowth of the results described in Chapter
2, in which a loss of total miRNA lead to increased NK cell function. We thus sought to identify
miRNAs that were upregulated upon NK cell activation, with the hypothesis that activationinduced upregulation would signify a contribution of that miRNA to the activation phenotype,
acting to inhibit further activation and NK cell function. Alternatively, a miRNA could be
upregulated upon activation to further promote the activation phenotype.
Thus, we used an IFN-γThy1.1 mouse,135 in which Thy1.1 is knocked-in to the IFN−γ locus,
and is expressed on the cell surface of IFN−γ-producing cells, allowing us to sort those cells that
were activated and compare their miRNA profile to that of non-activated cells. In collaboration
with Xiaowei Wang, we used a multiplex approach to compare the expression of 96 different
miRNAs of short-term activated and resting NK cells. We found that miR-155 was highly
upregulated either in Thy1.1+ NK cells after activation with IL-12 and IL-15 (Figure 4.1A), as well
as in bulk activated populations as compared to bulk resting NK cell populations (Figure 4.1B).
We thus focused on miR-155 as a potential contributor to an NK-cell activation
phenotype, and obtained a miR-155 knockout mouse (155-/-), as well as a miR-155
overexpression (LoxP-STOP-LoxP knocked in to the Rosa26 locus, 155FOE) mouse, which we
crossed to an Ncr1-iCre mouse to generate a novel NK cell-specific model of miR-155
overexpression. Consistent with our hypothesis that miR-155 was involved in activation, we
found that 155-/- NK cells produced more IFN−γ after activation. However, we were surprised to
find that 155FOE NK cells also produced more IFN−γ after activation.
While these experiments were being performed, Trotta et al showed that NK cells
overexpressing miR-155 had increased IFN−γ and NK cells with an anti-miR-155 or Bic-/- NK
cells had reduced IFN−γ production.60 The results for the Bic-/- conflicted with our miR-155-/-
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results. We reasoned that this might be because their experiments focused on the production of
IFN−γ after 12+18 stimulation, and at only a single timepoint of 24 hours, or that our model of
miR-155 deficiency was more highly backcrossed to a C57Bl/6 background. Zawislak, et al later
reported that miR-155 deficiency led to more a mature NK cell population, with various defects
in homeostasis and proliferation after MCMV infection.136 They also found that miR-155
deficiency led to increased IFN−γ production after in vitro activating receptor ligation, which was
consistent with our findings, while producing less IFN−γ after activation with cytokines,
consistent with the results reported for the Bic-/- and inconsistent with our findings. Trotta, et al
later published an additional report demonstrating that miR-155 transgenic overexpression led
to dramatic increases in proliferation, increased NK cell percentages, and numbers.73 We did
not find the 155FOE mice to have any of these phenotypes. As the level of overexpression of
miR-155 was similar in both of these mouse models, this suggests that disparate miR-155
overexpression was not the explanation. The 155FOE is NK cell-specific, tracked using a Crereporter allele, and was analyzed on a B6 background. We suspect that cell specificity of miR155 overexpression, strain of the mice used in the different models, or integration effects may
play a role in the different phenotypes observed in these models.
Thus, in order to address the numerous differences between the reported models, we sought to
directly compare, for the first time, NK cells specifically overexpressing miR-155 to those with a
loss of miR-155. The results of this work were published in The Journal of Immunology in 2013
and this chapter is adapted from that manuscript.79 These results advance our understanding of
miR-155’s function in NK cells, and demonstrate that NK cells display an exquisite balance
between a resting state and activated state, which can be easily manipulated by a shift of miR155 in either direction.
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Figure 4.1
miRNA expression profiles of activated NK cells.
IFN-γThy1.1/+ spleens were stimulated with IL-12+IL-15 or IL-15 only for 5 hours, and were then
sorted for Thy1.1+ and Thy1.1- NK cells (indicating IFN-γ expression or a lack of IFN-γ
production, respectively). These cells were analyzed for miRNA expression by 96-plex
analysis.137
(A) miRNA expression differences in Thy1.1+ NK cells v. Thy1.1- NK cells after IL-12+15
activation.
(B) miRNA expression differences in activated v. resting NK cells.
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Chapter 4: Abstract
NK cells are innate lymphocytes important for host defense against viral infections and
malignancy. However, the molecular programs orchestrating NK cell activation are incompletely
understood. miR-155 is markedly upregulated following cytokine activation of human and mouse
NK cells. Surprisingly, mature human and mouse NK cells transduced to overexpress miR-155,
NK cells from mice with NK cell-specific miR-155 overexpression, and miR-155-/- NK cells all
secreted more IFN-γ compared to controls. Investigating further, we found that activated NK
cells with miR-155 overexpression had increased per cell IFN-γ with normal IFN-γ+ percentages,
whereas greater percentages of miR-155-/- NK cells were IFN-γ+. In vivo MCMV-induced IFN-γ
expression by NK cells in these miR-155 models recapitulated the in vitro phenotypes. We
performed unbiased RISC-Seq on WT and miR-155-/- NK cells, and found that mRNAs targeted
by miR-155 were enriched in NK cell activation signaling pathways. Using specific inhibitors, we
confirmed these pathways were mechanistically involved in regulating IFN-γ production by miR155-/- NK cells. These data indicate that miR-155 regulation of NK cell activation is complex, and
that miR-155 functions as a dynamic tuner for NK cell activation via both setting the activation
threshold as well as controlling the extent of activation in mature NK cells. In summary, miR155-/- NK cells are more easily activated, through increased expression of proteins in the PI3K,
NF-κB, and calcineurin pathways, and miR-155-/- and 155-overexpressing NK cells exhibit
increased IFN-γ production through distinct cellular mechanisms.
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Chapter 4: Introduction
Natural killer (NK) cells are innate immune lymphocytes important for host protection against
infection and mediate anti-tumor effector responses, especially against hematologic
malignancies.100,110 NK cells develop from the common lymphoid progenitor along with T and B
cells,138 but undergo a distinct developmental pathway without DNA rearrangement of a clonal
antigen receptor. Mature NK cells integrate activating and inhibitory signals mediated by a wide
variety of surface receptors.139 These receptors signal through intracellular or adaptercontaining ITAM/ITIM motifs.31 Upon cytokine receptor activation, NK cells acquire enhanced
functional competence and also produce NK cell-derived cytokines/chemokines, including IFN-γ,
GM-CSF, TNF-α, and MIP1-α.110 When triggered through cell surface receptors, NK cells
release cytotoxic granules and kill target cells.113 It is through these primary functions that NK
cells provide a rapid response to infected or tumor target cells, as well as participate in complex
cross-talk with other immune cell types.
In the physiologic setting of a complex receptor-ligand environment, NK cells continually adapt,
highlighted by studies in which transgenic overexpression of activating receptor ligands leads to
NK cell functional anergy,33 or transfer of NK cells from an MHC-class I sufficient environment
into an MHC-class I deficient environment, where the NK cells rapidly become hypofunctional.34
This ability of NK cells to adapt to their environment by altering their functionality is summarized
by a model known as the tuning or ‘rheostat’ model,32 which proposes that the relative strength
of the activating and inhibitory signals that an NK cell receives tunes up (arms) or down
(disarms) the NK cell responsiveness. This education process both prevents inappropriate NK
cell activation, which could lead to autoimmune inflammation and disease, and is responsible for
graft-versus-leukemia effects, by setting a threshold for activation.26 While some of the
molecular events responsible for regulating NK cell activation and tuning have been defined,35,36
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our understanding of the molecules and intracellular changes that control these processes are
incomplete.
microRNAs (miRNAs) are a family of small, non-coding RNAs that mediate downregulation of
targeted mRNA transcripts by binding to complementary sites primarily in the 3’UTRs of
mRNAs.140 miRNAs have been shown to have a wide variety of roles in cancer,141
inflammation,142 and immune responses.71 In NK cells, miRNAs have been shown to regulate
NK cell proliferation, survival, and alter functionality.70,88,98 Recently, individual miRNAs have
been shown to influence NK cell development and function,143–145 including miR-155.60,73
miR-155 is encoded within the BIC non-coding RNA, and its role in T cells, B cells, and
macrophages has been characterized.52,56,57,59 miR-155 is expressed in resting NK cells,65 and
has been shown to be overexpressed in NK cell type lymphoma/leukemia.143 A recent report
has identified that miR-155 regulates IFN-γ production by human NK cells partially via
repression of SHIP-1, a phosphatase involved in negative regulation of PI3K signaling.60 In
addition, mice expressing a Lck-driven miR-155 transgene have NK cell IFN-γ alterations,
further linking miR-155 repression of SHIP1 to NK cell activation.73 miR-155 deficient mice were
further found to have alterations in murine cytomegalovirus (MCMV) responses.146 However,
mice that are deficient in miR-155 (155-/-), or that over-express miR-155 in an NK cell-restricted
fashion (155FOE), have not been directly compared and evaluated in depth for alterations in NK
cell responses.
Here, we compared the effects of multiple miR-155 alterations, including lentiviral
overexpression in mature human and murine NK cells, as well as NK cells from 155-/- and
155FOE mouse models. Unexpectedly, both 155FOE and 155-/- NK cells exhibit an augmented
IFN-γ response. We found that 155-/- NK cells had increased IFN-γ secretion due to an
increased percentage of IFN-γ+ NK cells without a change in per-cell expression, indicating a
novel role for miR-155 in altering the NK cell activation threshold. Conversely, 155FOE NK cells
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produced more IFN-γ per cell. The cellular mechanism for miR-155’s dual effect on IFN-γ was
recapitulated in vivo during MCMV infection of 155-/- and 155FOE mice. Notably, 155-/- mice had
decreased MCMV titers, suggesting that the increased functionality of 155-/- NK cells has a
biologically significant impact on the early NK-mediated anti-viral cytokine response. Utilizing
RISC-Seq analysis of activated NK cells from WT and 155-/- mice, we identified and validated
novel miR-155 mRNA targets in NK cells. We further used chemical inhibitors of multiple
activation pathways to eliminate IFN-γ production differences, indicating that miR-155
extensively regulates molecules involved in NK cell activation, thereby regulating the NK cell
activation threshold.
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Chapter 4: Results
miR-155 expression is markedly upregulated after NK cell activation in vitro and in vivo
miR-155 is moderately expressed in resting mouse NK cells when evaluated by next-generation
small RNA sequencing (Figure 4.2A).65 However, miR-155 is markedly upregulated after
cytokine activation, especially after stimulation with IL-12, IL-15, and IL-18 (Figure 4.2B and
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).

This upregulation was consistent between human and murine NK cells (Figure 4.2B).
Furthermore, miR-155 is induced in murine NK cells hours after infection with MCMV (Figure
4.2C). This corresponds to the peak of IFN-γ production by splenic NK cells (Figure 4.2D,
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Therefore, miR-155 expression is markedly increased in both mouse and human NK cells after
in vitro stimulation and in the context of a physiologic anti-viral response.
Overexpression of miR-155 in mature mouse and human NK cells augments activation-induced
IFN-γ
Because miR-155 expression increases in activated NK cells, we evaluated the impact of forced
lentiviral (LV) over-expression of miR-155 on the IFN-γ response in both mouse and human NK
cells. Both control LV-GFP and LV-GFP/155 were able to efficiently transduce human and
mouse NK cells (data not shown), and LV-GFP/155 virus resulted in miR-155 overexpression in
resting and cytokine-activated mouse and human NK cells (Figure 4.3A). Mature NK cells
transduced with LV-GFP/155 or LV-GFP control were sorted for GFP+ NK cells, and stimulated
to secrete IFN-γ. When miR-155 was over-expressed, we observed enhanced IFN-γ production
in human NK cells after stimulation with IL-12 plus IL-18, but not IL-12 plus IL-15 alone, due to a
high degree of human donor variability (Figure 4.3B). miR-155 overexpression also increased
the MFI of staining with an anti-CD158b1/b2/j mAb (but not other KIRs) on the surface of human
NK cells. Similar experiments with mature splenic WT NK cells showed that mature mouse NK
cells transduced with LV-GFP/155 also produced more IFN-γ protein when stimulated with IL-12
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plus IL-18, or with IL-12 plus IL-15 (Figure 4.3C). Therefore, forced overexpression of miR-155
results in increased IFN-γ production.
NK cells from 155-/- mice have an intact NK cell compartment and enhanced cytokine-induced
IFN-γ production
In order to further investigate the role of miR-155 in regulating NK cells, we examined 155-/mice (Figure 4.4A, Thai et al., 2007). An in depth characterization of the NK cell compartment in
155-/- mice found no changes in NK cell numbers, percentages, development, maturation,
survival, or homeostasis from all tissues examined. NK cells from 155-/- mice have normal
expression of most NK cell receptors, although we observed significantly decreased expression
of Ly49G2 and a slight increase in Ly49A expression. Therefore, prior to activation, 155-/- NK
cells appear similar to WT B6 NK cells. Because NK cells transduced to overexpress miR-155
produced more total IFN-γ, we expected that the 155-/- NK cells would have the opposite
phenotype: decreased IFN-γ production after activation. However, we were surprised to find that
the 155-/- NK cells secreted more IFN-γ after stimulation with IL-12 plus IL-15 (Figure 4.4B) or IL12 plus IL-18 (Figure 4.4C) as measured by ELISA. Furthermore, 155-/- NK cells produce more
granzyme B upon stimulation with IL-15, and have increased levels of surface CD107a after
NK1.1 ligation suggesting a global enhancement in responses following activation or triggering.
We confirmed that Ly49G2 and Ly49A expression was not associated with this IFN-γ
phenotype, and 155-/- and control NK cells had similar Ly49C-based licensing ratios. Despite this
increase in global activation, the killing of YAC-1 tumors by 155-/- and control NK cells after 48
hours of IL-15 stimulation was not significantly different. This may reflect an alteration of
threshold following high-dose IL-15 stimulation in vitro. Collectively, these data suggest that 155/-

NK cells are more responsive to activation.

Mice with NK cell-specific miR-155 overexpression (155FOE) have a normal NK cell compartment
and produce more IFN-γ following activation
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We hypothesized that the incongruous phenotype between 155-/- and LV-GFP/155 models could
be explained by in vitro culture and/or lentiviral transduction. To further investigate this premise
we generated a conditional miR-155 overexpression knock-in model,56 combined with an NK
cell-specific Cre (Ncr1-iCre),77 to allow for specific miR-155 overexpression in NK cells (155FOE).
In this model, miR-155 overexpression commences at an early stage of dedicated NK cell
development and persists throughout the lifespan of the mature NK cell, with Cre+ NK cells
marked by GFP (NK cells routinely >85% Cre+). Cre+ NK cells from 155FOE mice exhibit
increased miR-155 expression, compared to both WT Cre+ NK cells, or the small number of CreNK cells within 155FOE mice (Figure 4.5A). Similar to 155-/- mice, resting 155FOE NK percentages,
numbers, maturation, surface receptor expression, and ex vivo expansion were normal, with the
exception of an increased percentage of Ly49G2+ NK cells. We next investigated IFN-γ
production by cytokine-activated 155FOE NK cells. Sorted GFP+ 155FOE NK cells or control Cre+
(RosaYFP) NK cells were stimulated with IL-12 plus IL-15 or IL-12 plus IL-18 and analyzed for
IFN-γ production by ELISA (Figure 4.5B,C). In this model, IFN-γ production was also increased
after stimulation, compared to controls. Therefore, forced miR-155 overexpression initiated early
in NK development again lead to increased total IFN-γproduction in mature mouse NK cells.
Distinct cellular mechanisms are responsible for enhanced IFN-γ production by 155-/- versus
155FOE NK cells
In an effort to better understand the seemingly disparate finding that both 155-/- and 155FOE NK
cells produce more IFN-γ than control NK cells, we investigated per-cell IFN-γ production by
intracellular flow cytometry. We found that 155-/- NK cells had an increased percentage of IFN-γ+
NK cells following activation with NK1.1 ligation, IL-12 plus IL-15, or IL-12 plus IL-18 (Figure
4.6A,C-E), with either no change or a modest reduction of IFN-γ protein per NK cell, determined
by median fluorescence intensity (MFI) (Figure 4.6A,F-H). In contrast, NK cells from 155FOE
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mice had increased per NK cell expression of IFN-γ (MFI) following activation with NK1.1
ligation or IL-12 plus IL-15 (Figure 4.6B, F-H), without alterations in the percentage of NK cells
responding (Figure 4.6B, C-E). In the IL-12 plus IL-18 experiments, the percentage positive and
MFI for IFN-γ was maximal in control NK cells, thereby providing a minimal dynamic range to
detect IFN-γ increases after miR-155 alteration. Since our genetic mouse models of miR-155
loss and overexpression in NK cells revealed different cellular mechanisms of enhanced IFN-γ
production, we analyzed per NK cell IFN-γ production in mature human and mouse NK cells
following lentiviral overexpression of miR-155. Consistent with 155FOE mice, LV-GFP/155
transduced human and mouse NK cells demonstrated increased IFN-γ production per NK cell,
as well as an increased percentage of IFN-γ+ NK cells in LV-GFP/155 compared to control NK
cells. The net sum of the percentage of IFN-γ+ NK cells and the amount of IFN-γ produced by
each cell recapitulates and explains the increased total IFN-γ measured by ELISA in both of
these models (Figs. 4.2-4.4), suggesting a role for an activation threshold alteration in the 155-/NK cells. Indeed, α-NK1.1 mAb dilutions revealed a concentration at which 155-/- NK cells
produced IFN-γ, but WT NK cells did not (Figure 4.6I). Though these differences occur primarily
in Ly49C+ cells, which are the primary IFN-γ producers, we observed no alterations in the
licensing ratio in the 155-/- NK cells. Therefore, distinct cellular mechanisms explain the
phenomenon of increased total IFN-γ production in all three models.
MCMV infection recapitulates in vitro IFN-γ responses of 155-/- and 155FOE NK cells, and leads to
decreased viral titers in 155-/- mice
To determine whether or not the increased activation of 155-/- NK cells was relevant in vivo, we
infected 155-/- and B6 WT mice, or 155FOE and RosaYFP control mice, with MCMV. At 36 hours
postinfection (p.i.), an increased percentage of 155-/- NK cells responded to MCMV infection by
producing IFN-γ (Figure 4.7A-C), compared to control NK cells. In contrast, 155FOE NK cells had

76

increased IFN-γ MFI with no alteration in the IFN-γ+ NK cell percentage (Figure 4.7D-F).
Therefore, these in vivo results recapitulated the in vitro IFN-γ phenotype. We next evaluated
whether the increased NK cell-derived IFN-γ at 1.5 days p.i. affected the course of MCMV
infection by measuring MCMV viral titers of 155-/- mice at 3 days p.i. (Figure 4.7G). 155-/- mice
had decreased MCMV titers at 3 days p.i., consistent with the observed enhanced IFN-γ
response. Thus, NK cells from 155-/- mice exhibit enhanced early IFN-γ production during the
cytokine-dependent phase, and miR-155 disrupts the anti-MCMV NK cell response.
RISC-Seq identifies novel miR-155 targets in multiple NK cell activation pathways
In order to determine relevant targets of miR-155 involved in threshold and IFN-γ production,
WT and 155-/- NK cells were activated with IL-12, IL-15, and IL-18 for 24 hours to induce mRNA
targets that are likely regulated by miR-155 at its peak expression level in NK cells. We then
sequenced (RISC-Seq) paired total RNA and RNA from immunoprecipitated RNA-Induced
Silencing Complex (RISC), which contains miRNAs and their targets from both WT and 155-/NK cells.93,147 An mRNA transcript that is a target of miR-155 is expected to be enriched in the
RISC of WT NK cells compared to 155-/- NK cells (i.e., a RISC incorporation ratio, RIR, > 1)
(Figure 4.8A). To improve the signal/noise ratio of this analysis, we filtered by predicted miR155 targets in TargetScan (Figure 4.8B).148 This resulted in marked enrichment of targets with a
RIR > 1.2, with an almost complete loss of targets with a RIR < 0.83. This filter approach did not
produce any mRNA target enrichment when performed with an irrelevant miRNA target
prediction. We next biochemically validated miR-155 targets identified using miR-155
overexpression coupled with a luciferase sensor plasmid containing the 3’UTR of the putative
target mRNAs (Fehniger et al., 2010; Sullivan et al., 2012) (Figure 4.8C) and Western Blot of
155-/- and WT NK cells for SHIP1, SLP-76, and IKBKE (Figure 4.8D). Notably, all candidates
identified by RISC-Seq that were tested by either luciferase assay or Western blot were
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confirmed to be true miR-155 targets by these validation methods. Together, these data indicate
that miR-155 targets multiple molecules in NK cell activation pathways.
mRNA transcripts with a RIR > 1 standard deviation from the mean were analyzed using DAVID
pathway analysis, and the KEGG lymphocyte (T cell) activation pathway was found to be
significantly overrepresented. We hypothesized that the decreased activation threshold of 155-/NK cells was due to an increase in the protein levels of the miR-155-targeted members of this
pathway, and that treatment with specific inhibitors would elucidate the proteins critical for miR155 threshold effects. In order to directly test these confirmed targets in the acquisition of a
decreased threshold of activation in the 155-/- NK cells, we utilized chemical inhibitors of NK cell
activation pathways; specifically, PI3K (Ly294002), calcineurin (cyclosporin A), and NF-κB (BAY
11-7082). We utilized these inhibitors in an NK1.1 ligation assay, since this stimulus
demonstrated the greatest threshold effect. We found that inhibition of either calcineurin (Figure
4.9A) or PI3K (Figure 4.9B) led to a dose-responsive decrease in the differential between 155-/and WT NK cell IFN-γ production, while inhibition of NF-κB led to a differential response only at
concentrations above its IC50 (Figure 4.9C), and an inhibitor of p38 Kinase, SB203580, had no
effect on IFN-γ production (Figure 4.9D). These data indicate that the PI3K and calcineurin
pathways contribute to the increased production of IFN-γ in 155-/- NK cells, and collectively, form
the basis of the decreased threshold of activation in these cells (Figure 4.9E).
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Chapter 4: Discussion
In this study, we assessed the impact of miR-155 alterations in human and mouse NK cells
using lentiviral overexpression, as well as genetic mouse models of global miR-155 deficiency
and NK-specific miR-155 overexpression. We demonstrate that miR-155 is induced upon
cytokine activation of both mouse and human NK cells in vitro, as well as in vivo during an
ongoing NK cell response to MCMV. We confirmed results of a previous study,60 showing that
miR-155 overexpression in mature human NK cells leads to increased IFN-γ production
following NK cell activation. Furthermore, we found identical results in mature mouse NK cells,
demonstrating consistent miR-155 regulation of NK cell activation in mice and humans in this
context. However, we unexpectedly discovered that 155-/- NK cells also produced more IFN-γ
upon cytokine activation. How can miR-155 overexpression and deficiency lead to similar IFN-γ
phenotypes in NK cells? To address this, we generated a novel 155FOE model that specifically
overexpresses miR-155 in developing and mature NK cells, finding that similar to lentivirustransduced NK cells that overexpress miR-155, 155FOE NK cells also secreted increased
amounts of IFN-γ upon activation. We hypothesized that miR-155 loss or overexpression had
distinct mechanisms that lead to similar apparent IFN-γ phenotypes. Indeed, a higher proportion
of NK cells from 155-/- mice produced IFN-γ following activation, whereas NK cells from 155FOE
mice exhibited increased per NK cell expression of IFN-γ following activation. These findings, in
multiple complementary experimental systems, suggest a dual role for miR-155 by regulating
NK cell activation and cytokine production. When miR-155 is deficient during NK cell
development and maturation (e.g., 155-/-) the NK cell threshold for future activation is lowered,
allowing more NK cells to express IFN-γ when stimulated. In contrast, forced overexpression of
miR-155 in NK cells, either in vitro (lentiviral) in mature NK cells, or in vivo (155FOE) in
developing NK cells, allows an NK cell, once it crosses the activation threshold, to have an
amplified IFN-γ response. This is likely due to the previously postulated mechanism of miR-155
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negatively regulating SHIP-1, a negative regulator of IFN-γ production. While the Ly49C+/Ly49Cratio of IFN-γ production (the licensing ratio) is not altered per se, we do note that the vast
majority of IFN-γ producing cells in these mice are Ly49C+, and thus the licensed subset of NK
cells is the major subset affected by miR-155 loss. It remains possible, therefore, that miR-155
may have a role in NK cell licensing. Licensing alterations in both the 155-/- and the 155FOE NK
cells are an area of ongoing study. Furthermore, since LV-GFP/155 NK cells develop in a
context of normal levels of miR-155, while 155FOE NK cells develop with increased levels of miR155, the increased percentage of activated NK cells in the LV-GFP/155 further supports a
developmental/maturation role for miR-155 in suppressing future activation via threshold
modulation. Thus, the combined use of both human and murine mature NK cells in concert with
genetic mouse models provides a comprehensive picture of the complex role of miR-155 in
directing NK cell activation and IFN-γ production (Figure 4.10).
The findings presented here that both mature human and mouse NK cells that overexpress
miR-155 exhibit enhanced IFN-γ production upon activation are in agreement with a recent
study focused primarily on human NK cells.60 Furthermore, the enhanced NK cell IFN-γ
phenotype demonstrated in 155FOE mice was also observed in a recent report in an Lck-miR155 transgenic mouse model.73 However, the Lck-miR-155 transgenic mice were reported to
have increased NK cell percentages, numbers, and proliferation, while the 155FOE mice had a
normal complement of NK cells in all tissues examined. The level of overexpression of miR-155
was similar in both of these mouse models, suggesting that disparate miR-155 overexpression
was not the explanation. The 155FOE is NK cell-specific, tracked using a Cre-reporter allele, and
was analyzed on a B6 background. We suspect that cell specificity of miR-155 overexpression,
strain of the mice used in the different models, or integration effects may play a role in the
different phenotypes observed in these models.
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What are the downstream targets that are responsible for miR-155’s effects in mature NK cells?
miR-155-target mRNAs have been shown to be cell-context specific,61 and thus we demonstrate
here the first miR-155 target set in primary NK cells. Here we report a RISC-Seq approach that
identified >20 high probability candidate mRNA targets, and validated many using luciferase
sensor assays and Western blot. Notably, this included SHIP-1 (Inpp5d), which has been
previously identified and validated as a target of miR-155.59,60 Indeed, specific knockdown of
SHIP-1 has been shown to phenocopy miR-155 deletion in macrophages. SHIP-1 functions as a
negative regulator of IFN-γ production, and thus miR-155 inhibition of SHIP-1 in activated NK
cells should result indirectly in greater IFN-γ production. Our data fit with this model of miR-155
directly targeting SHIP-1, with increased IFN-γ MFI in LV-GFP/155 and 155FOE NK cells, and a
modestly decreased IFN-γ MFI in some activating conditions in our 155-/- NK cells. Further, a
recent study has shown that SHIP-1 deficiency in developing NK cells, contrary to what would
be expected for deletion of a negative regulator of activation, actually leads to a decreased
percentage of mature cells becoming IFN-γ positive after stimulation.149 These findings are
provocative and consistent with our data, because miR-155 deletion would lead to increased
SHIP-1 levels in development, and therefore may alter the NK cell activation threshold, leading
to increased IFN-γ percentages in mature NK cells. This concept is similar to the known TCR
signal amplitude tuning by miR-181a targeting of multiple phosphatases, identified in T cells.128
Thus, SHIP-1 represents one validated miR-155 target that may contribute to the NK cell
phenotype. However, previous studies examining NK cell SHIP-1 gain-of-function resulted in
only a partial restoration of the NK cell activation phenotype,60 suggesting that targets other than
SHIP1 play a role in this phenotype.
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Here, we identified a number of these additional miR-155 mRNA targets directly in primary NK
cells in our RISC-Seq experiments. A number of miR-155 NK cell mRNA targets are important
members of signaling cascades central to NK cell activation, providing an alternative
explanation for how miR-155 may tune the activation threshold of NK cells (Figure 4.9).
Additionally, we found that novel targets identified in the PI3K, NF-κB, and calcineurin pathways
are able to contribute to the increased IFN-γ production in NK cells, as chemical inhibition of
these pathways results in a loss of the enhanced IFN-γ production phenotype, though to a far
lesser extent for NF-κB, indicating that this pathway is less important for miR-155’s impact on
IFN-γ. Thus, these additional miR-155 targets in the NK cell activation pathway contribute to NK
cell activation phenotypes. The individual and collective contribution of these targets to tuning
the NK cell threshold will be evaluated further in future studies.
We also demonstrate a regulatory role for miR-155 during early anti-viral NK cell responses in
vivo, with effects on early cytokine-dependent IFN-γ production. IFN-γ production by 155-/- NK
cells was increased in vivo at day 1.5 post-MCMV infection, which correlated with a decreased
viral titer at 3 days, and was consistent with our in vitro cytokine-dependent IFN-γ phenotype.
MCMV studies of 155FOE mice are ongoing. These findings may have powerful implications in
the human NK cell response to MCMV, and extending the study of miR-155 in this setting is of
exceptional interest. A recently published study
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identified SOCS1 and Noxa as targets of

miR-155, and demonstrated a blunted Ly49H+ expansion at later time points. Future studies in a
miR-155 floxed knock-out model that selectively lacks miR-155 in NK cells will be used to
investigate the NK cell intrinsic role of miR-155.
In this study we have defined a novel dual role for miR-155 in the regulation of both mature NK
cell IFN-γ production and setting a threshold of activation during NK cell development and
maturation (Figure 4.10). This regulation of activation by miR-155 is evident both in vitro and in
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vivo during an NK cell response to viral infection. While SHIP-1 represents a validated target of
miR-155 that is likely important in these processes, novel mRNA targets in activation signaling
pathways identified here contribute to setting the NK cell activation threshold. miR-155 also
regulates the NK cell IFN-γ response during MCMV infection, indicating that the observed miR155-mediated changes in IFN-γ influence host defense against a viral pathogen. These findings
further support the role for miR-155, and miRNAs in general, as ‘tuners’ of immune cell
activation. Future studies of miR-155, especially in the context of cell-specific deletion or
overexpression, will undoubtedly uncover more of miR-155’s diverse functions in NK cells.
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Figure 4.2
miR-155 is expressed in NK cells and induced after NK cell activation in vitro and in vivo.
miR-155 expression was assessed by deep sequencing (A) or qPCR (B,C) after cytokine
stimulation (B) or MCMV infection (C).
(A) miR-155 is expressed in resting mouse NK1.1+CD3- splenic NK cells. Data shown are the
rank order of all expressed NK cell miRNAs by small RNA sequencing from mouse NK cells
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.

Sequencing reads were normalized to total miRNA reads and plotted as log2 (normalized read
counts) versus rank order of expression in resting NK cells. The large circle indicates miR-155.
(B) Human CD56+CD3- peripheral blood NK cells (left) and mouse NK1.1+CD3- splenic NK cells
(right) were enriched to >95% purity and evaluated for miR-155 expression at rest, or at the
indicated time points after cytokine activation. Relative fold change was assessed by miR-155
RT-qPCR. Data summarize 5 mice and 4 donors from 2-3 independent experiments.
(C) miR-155 is induced following MCMV infection in NK cells. Ly49H+ and Ly49H- NK1.1+CD3NK cells were sorted from the spleens of naïve control mice or control mice infected with MCMV
(5x104 pfu/mouse) at 1.5 or 7 days p.i. miR-155 mRNA levels were compared by RT-qPCR, and
found to be significantly increased in both NK cell subsets at 1.5 days p.i. Data summarize 10
mice from 3 independent experiments.

(D) Summary data showing the robust IFN-γ production at day 1.5 post-infection. Data
summarize 10 mice from 3 independent experiments.
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Figure 4.3
Overexpression of miR-155 in human and mouse mature NK cells results in increased
IFN-γ protein secretion.

(A) Relative miR-155 expression measured by qPCR from human and mouse LV-transduced
NK cells (mean ± SEM fold change), including both resting and IL-12+IL-18-stimulated NK cells.
Data summarize 5-6 donors from 3 independent experiments, and 4-12 mice from 2-3
independent experiments.

(B) IFN-γ protein production by human NK cells by ELISA after 12 hours of stimulation with the
indicated cytokines. Data summarize 8-10 donors from 2 independent experiments.

(C) IFN-γ protein production by mouse NK cells measured by ELISA after 12 hours of
stimulation with the indicated cytokines. Data show one experiment of two groups (n=2-3
mice/group), representative of 4 groups of n=2-3 mice, from 3 independent experiments. For (BC), data are shown as mean ± SEM IFN-γ concentration.
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Figure 4.4
NK cells from 155-/- mice have enhanced IFN-γ production.

(A) NK cells sorted from 155-/- mice express no detectable miR-155 at rest or following 24 hours
of IL-12+IL-15+IL-18 combined activation. Data shown (mean ± SEM fold change) are
normalized to WT resting NK cells and summarize 4 pools of 4-5 mice from 3 independent
experiments.

(B-C) 155-/- NK cells exhibit increased IFN-γ production after 6 or 12 hours of cytokine
stimulation. IFN-γ protein was measured by ELISA from cell-free culture supernatants after 6 or
12 hours with IL-12+IL-15 (B) or IL-12+IL-18 (C). Data shown are the mean ± SEM from one
experiment (2-3 mice/genotype), representative of 3 independent experiments.
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Figure 4.5
NK cells from 155FOE mice have increased levels of miR-155 and increased IFN-γ
production.
(A) miR-155 expression was measured using RT-qPCR in sorted resting WT GFP+ NK cells,
155FOE GFP- and GFP+ NK cells from the spleen, normalized to WT GFP+ NK cells with sno135
as the calibrator. Data summarize at least 3 mice per group from 3 independent experiments.

(B-C) IFN-γ secretion as measured by ELISA of cell-free supernatants by flow sorted GFP+ NK
cells after 6 or 12 hours of stimulation with IL-12+IL-15 (B) or IL-12+IL-18 (C). Data shown are
mean ± SEM IFN-γ concentration of one experiment of 2-3 mice per group, representative of 2
independent experiments.
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Figure 4.6
NK cells from 155-/- and 155FOE mice produce increased IFN-γ by different cellular
mechanisms.
(A-B) Representative intracellular IFN-γ flow cytometry histograms of 155-/- (A, light gray) and
155FOE (B, dark gray) compared to WT NK cells (A, black) or GFP+ control NK cells (B, black),
after stimulation with IL-12+IL-15 for 6 hours.
(C-E) Normalized summary data for percent IFN-γ positive NK cells (left) demonstrates a
significantly higher percentage of 155-/- NK cells are positive for IFN-γ, while 155FOE NK cells are
unchanged, compared to control NK cells.
(F-H) The IFN-γ expression on a per cell basis (MFI) of IFN-γ+ NK cells (right) was unaffected or
modestly decreased within 155-/- NK cells, while 155FOE NK cells exhibited a significant increase
in the expression of IFN-γ on a per cell basis, in all conditions except IL-12+IL-18.
(I) 155-/- NK cells are activated to produce IFN-γ at concentrations that do not activate WT NK
cells, indicating an activation threshold defect. Data in (C-H) summarize 5-20 mice per group
from 2-7 independent experiments. Data in (I) are from 3 mice per group in one experiment,
representative of three independent experiments.
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Figure 4.7

155-/- and 155FOE NK cells produce more IFN-γ during MCMV infection in vivo.

(A-C) Age and gender-matched 155-/- or B6 mice were infected with 5x104 PFU MCMV, and
splenic NK cells were assessed for intracellular IFN-γ production by flow cytometry after 36
hours. Representative flow plots (A) and summary data (B-C) showing increased mean ± SEM
IFN-γ+ percentage (B) and MFI (normalized to WT in each experiment) (C) of NK cells in 155-/mice, compared to WT controls at 36 hours p.i. Data summarize 6-7 mice per group from 2
independent experiments.

(D-F) Representative flow plot (D) and summary data (E-F) showing increased mean ± SEM
IFN-γ+ percentage (E) and MFI (F) of NK cells in 155FOE mice, compared to Cre+ controls at 36
hours p.i. Data summarize 4-6 mice per group from 2 independent experiments. (G) Groups of
MCMV-infected WT and 155-/- mice were assessed for splenic viral titers 3 days p.i. (mean ±
SEM viral titer). Dotted line represents the limit of detection for the assay (0.92). Data
summarize 7-8 mice/group from 2 independent experiments.
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Figure 4.8
RISC-Seq identifies miR-155 targets in NK cells.
(A) Unfiltered results of RISC-Seq, displayed as WT total RNA expression versus RISC
Incorporation Ratio (WT/155-/-). Graph depicted is limited to targets with a fold change between
0.5 and 2 to align with (B). 116 transcripts lie outside of these depicted boundaries, but none of
these were targets predicted by TargetScan. Targets validated in (C) are shown as predicted
(open circle) or not predicted (open square) by TargetScan, and the open diamond represents
SHIP1, a previously validated target. Numbers above graph represent the percentage of total
mRNA transcripts within each RISC Incorporation Ratio (RIR) quartile: Group 1: RI > 1.2, Group
2: 1 < RI < 1.2, Group 3: 0.83 < RI < 1, Group 4: RI < 0.83. Data represent 2 biological
replicates for groups of WT and 155-/- NK cells following IL-12, IL-15, and IL-18 activation.
(B) Dataset in (A) filtered by cross-referencing with miR-155 predicted targets (TargetScan).
(C) Luciferase validation in 293T cells of RISC-Seq targets, as indicated in (A) and (B). Data
summarize two independent experiments of duplicate wells.
(D) Western Blot analysis of miR-155 target expression in WT and 155-/- NK cells. Relative
overexpression for 155-/- NK cells is indicated.
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Figure 4.9
miR-155 targets NK cell activation pathways. (A-D) NK cells were activated via NK1.1
ligation using plate bound α-NK1.1 in the presence of an inhibitor of calcineurin (A), PI3K (B),
NF-κB (C), or p38 Kinase (D) to demonstrate loss of threshold differentials after including
inhibitors. Solid lines represent previously determined IC50 values (see Materials and Methods),
while dashed lines represent IC50 values obtained by our experiments. The data shown are
mean ± SEM and are representative of three independent experiments. (E) Model/summary of
miR-155’s role in targeting genes involved in the acquisition of NK cell threshold. RIR
Incorporation values are included with each gene. RISC-Seq-identified (RIR>1.2) miR-155
targets (dark box) and inhibitor targets (shaded box) are indicated.
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Figure 4.10
Model for miR-155’s role in NK cells.
(A) A summary of the effects of miR-155 alterations on a population of stimulated NK cells.
Black = unactivated, blue = activated with low IFN−γ production, red = activated with high IFN−γ
production.
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Chapter 5: MicroRNA-15/16 Antagonizes Myb to Control Natural Killer Cell Maturation
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Chapter 5: Preface
These studies fortuitously arose out of an initial finding, in our initial studies of global miRNA
deficiency, that miRNA-deficient NK cells produced an increased amount of IFN−γ. We
searched for miRNAs that were expressed in NK cells and targeted the IFN−γ 3’UTR, and found
that miR-15/16 targeted the 3’UTR of IFN−γ, and this inhibition was specific, as it could be
released by mutation of those specific sites. We thus obtained a LoxP-flanked miR-15a/16-1
allele from Ulf Klein and Riccardo Dalla-Favera,66 which we first crossed to a hCD2-Cre, and as
the studies progressed, to an NK-specific Cre.
We were surprised to find, initially, that contrary to our expectations, miR-15/16 deficient NK
cells had decreased IFN−γ (increased IFN−γ would be expected due to the loss of repression).
However, when we investigated further, we found that this was due to deficient maturation. As
the most mature NK cells are the best producers of IFN−γ in our assays, the loss of these cells
led to a defect in the overall IFN−γ production by NK cells. Indeed, when we corrected for
maturation, we found no defects in IFN−γ production. However, this does not entirely preclude a
role for miR-15/16 in IFN−γ regulation, as miR-15a/16-1 elimination does not affect the
expression of the other primary miR-15/16 locus, miR-15b/16-2.
However, the maturation phenotype that we identified is among the most severe that was
reported due to a miRNA deficiency, and miR-15/16 is one of the most highly expressed
miRNAs in NK cells. Because an additional finding of global miRNA deficiency was that miRNAdeficient NK cells had defective maturation, failing to reach the most mature stages of NK cell
development, we altered our hypothesis: Does miR-15/16 direct NK cell maturation? We found
that indeed, it does, through regulation of the transcription factor c-Myb.
While we were working on this study, Bezman et al published an investigation of the role of miR150 in NK cells, another highly expressed miRNA in NK cells.74 Using a miR-150-/- model, they
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found that NK cell maturation was impaired. They complemented this with a miR-150Tg model,
which had an increase in NK cell maturation as well as slightly increased percentages of NK
cells. They showed that miR-150 targeted Myb, and also used a Myb± mouse to phenocopy the
miR-150Tg, demonstrating that at least some of miR-150’s effects are likely mediated through
targeting of Myb in vivo.
As two distinct and highly expressed miRNAs (miR-15/16 and miR-150) both target Myb in NK
cells, it is reasonable to predict that Myb’s function in NK cell development and maturation is
highly important. Thus we investigated the role of Myb further, developing vectors to ascertain
the role of Myb in vivo. This work contributes greatly to our understanding of both a highly
expressed miRNA in NK cells, the miR-15/16 family, as well as a commonly-regulated gene,
Myb, in NK cell maturation.

104

Chapter 5: Abstract
NK cells develop in the bone marrow and complete their maturation in peripheral organs, but the
molecular events controlling maturation are incompletely understood. Utilizing an NK cellspecific miR-15/16 deficient genetic model (15a/16-1FKO), we identified a critical role for miR15/16 family microRNAs in the normal maturation of NK cells in vivo, with a specific reduction in
mature CD11b+CD27- NK cells in multiple tissues. The mechanism responsible was a block in
differentiation, since accelerated NK cell death was not evident, and earlier intermediates of NK
cell maturation were expanded. Further, we identified Myb as a direct target of miR-15/16 in NK
cells, with Myb expression increased in immature 15a/16-1FKO NK cells. Following adoptive
transfer, immature 15a/16-1FKO NK cells exhibited defective maturation, which was rescued by
ectopic miR-15/16 expression or Myb knockdown. Moreover, Myb overexpression resulted in
defective NK cell maturation. Thus, miR-15/16 regulation of Myb controls the normal NK cell
maturation program.
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Chapter 5: Introduction
Natural Killer (NK) cells are innate immune lymphocytes that are distinct from adaptive T and B
lymphocytes in developmental and functional properties.35,100,138 Although all lineages develop
from the common lymphocyte progenitor, NK cell development proceeds through a distinct set
of intermediates in the bone marrow (BM), where they undergo an education process and
become functionally competent.150 NK cells further mature in the periphery, with changes in
function marked by different cell surface proteins including CD11b, CD27, CD43, and CD62L.8
In the most common NK cell maturation classification, increased maturation correlates with
decreasing proliferative capacity and increasing functional capacity as defined by a 4-stage
model in which NK cells mature from CD27-CD11b- (Stage I) to CD27+CD11b- (Stage II),
CD27+CD11b+ (Stage III), and finally CD27-CD11b+ (Stage IV).11,12 This functional capacity
includes the release of immunomodulatory cytokines, such as interferon gamma (IFN-γ),
through stimulation of surface receptors such as NK1.1, Ly49H, and NKG2D, as well as
cytokine signals such as those provided by IL-12, IL-15, and IL-18,31,110,151 and the release of
cytotoxic granules, containing granzyme B (GzmB) and perforin (Prf1), onto the surface of target
cells, thereby killing those cells.113,152 Thus, effective NK cell functional responses depend on
appropriate maturation events in the periphery.
Despite the known functional differences between immature and mature NK cells, our
understanding of the molecular networks governing NK cell maturation remains limited.36,153
Early NK cell development is controlled by factors such as Nfil3,154 Id2,155 Hnf1a(Tcf-1),156 and
Tox.157 Of these, Nfil3 has been shown to be the most specific for the NK lineage, but is critical
only in early NK cell development, and its requirement can be superseded by activation
receptor-driven expansion.158 In later differentiation numerous factors are required, such as
Gata3,159 Prdm1 (Blimp1),13 Ets1,14 T-bet,160 and Eomes.161 Additional molecular mechanisms
regulating NK cell maturation remain to be elucidated.
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MicroRNAs (miRNAs) are small, 18-22 nucleotide non-coding RNAs that regulate protein
production by binding to semi-complementary sites in the 3’UTR of target mRNAs.140 miRNAs
have been shown to be critical to the regulation of a wide variety of processes in nearly all cell
types. In lymphocytes, a number of miRNAs have been shown to control the development and
regulation of immune responses,46,71 although few studies of miRNA regulation of NK cell
biology have been reported.144 miRNAs are organized into families by sequence relationship,
one of which is the highly conserved miR-15/16 family,62 consisting of miR-15a, miR-15b, miR16, miR-195, miR-322, miR-424, miR-503, miR-497, and miR-1907. In lymphocytes, miR-15a,
miR-15b, and miR-16 are the major constituents of the miR-15/16 family. These miRNAs are
highly expressed,63–65 and have been found to inhibit B cell proliferation,66 and promote cellular
apoptosis.67 miR-15a, miR-15b, and miR-16 are transcribed from two distinct genomic loci, the
miR-15a/16-1 cluster, and the miR-15b/16-2 cluster, and all three miRNAs share a high degree
of homology and predicted targets. The miR-15a/16-1 cluster is located intronic to the DLEU2
gene, known to be deleted in chronic lymphocytic leukemia,68 and the miR-15b/16-2 cluster is
found intronic to the SMC4 gene, with a putative function in the structural maintenance of
chromatin.69 The miR-15/16 miRNA family contribution to the regulation of NK cell biology is
unknown.
Myb is the prototypical transcription factor of the Myb family,162 which includes Myb, Mybl1 (aMyb), and Mybl2 (b-Myb), and operates primarily as a transcriptional activator through binding
of the sequence t/cAACt/gG.163 A viral form of Myb is carried by the avian leukemia retroviruses
AMV and E26, and multiple viruses are known to insert in a regulatory region at the 5’ end of
Myb, driving constitutive expression and augmented proliferation.164 Myb is required for normal
hematopoiesis, and the Myb global genetic knock-out is embryonic lethal in mice due to
hematopoietic failure.165 Myb is predicted to be regulated by a number of miRNAs, including
miR-15/16.166 Another miRNA highly expressed in NK cells, miR-150, was recently shown to
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target Myb in B cells,167 with deletion of miR-150 leading to enhanced proliferation and defective
B cell differentiation. miR-150 has also been shown to be important in NK and NK-T cells,74,168
with its deletion leading to defects in the development and maturation of NK cells, potentially
through its role in regulating Myb. Therefore, Myb is a transcription factor important for
lymphocyte development, and the regulation of its expression in NK cells remains an important
question in lymphocyte biology.
Here, we report a novel mouse model of NK cell-specific miR-15/16 deficiency that exhibits
defective NK cell maturation. Investigation of mRNA differences between miR-15/16-deficient
and -sufficient NK cells identified Myb as a primary candidate for mediating this maturation
phenotype. Consistent with this mechanism, the Myb 3’UTR is a direct target of miR-15/16, and
Myb protein levels were increased in miR-15/16-deficient immature NK cells. Utilizing lentiviral
gene expression in primary NK cells followed by adoptive transfer, a role for miR-15/16
restoration or Myb knockdown restored defective NK cell maturation in vivo. Thus, miR-15/16
and Myb are critical for the normal maturation of NK cells.
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Chapter 5: Results
miR-15/16 is highly expressed in NK cells, and is predicted to target genes involved in cell
proliferation and differentiation
The miR-15/16 family is highly conserved, and highly expressed in both mouse and human NK
cells. As a family, mature miR-15/16 miRNA sequences are one of the most highly expressed
miRNAs in mouse NK cells as detected by Illumina miR-Seq (Figure 5.1A).65 miR-15/16 is
predicted to target a number of genes involved in fundamental pathways such as development,
protein modification, intracellular signaling, cell cycle, and cell proliferation and differentiation
(Table S1).148,169 In order to investigate the NK cell-intrinsic role of miR-15/16, we generated a
model of NK cell-specific miR-15/16 deficiency by combining a conditional (LoxP-flanked) miR15a/16-1 allele,66 with an NK cell-specific Cre recombinase (Ncr1-iCre) (Figure 5.1B),77 which
results in excision of mir-15a/16-1 in NK cells. As previously reported, this Cre model results in
~85% excision exclusively in NK cells as measured by a Rosa-YFP reporter,79 and except
where indicated, YFP is included in all analyses to accurately report Cre+ NK cells. We
assessed miR-15/16 family levels in Ctrl (Ncr1-iCre x miR-15a/16-1WT/WT) or 15a/16-1FKO
(Ncr1-iCre x miR-15a/16-1F/F) cells using qRT-PCR (Figure 5.1C), and observed that in 15a/161FKO YFP+ NK cells, miR-15a was undetectable, miR-16 was 60% reduced, and miR-15b
levels were normal, as expected. Therefore, this model eliminates approximately 50% of the
overall miR-15/16 family expression in Cre-expressing (YFP+) NK cells.
miR-15a/16-1FKO mice exhibit defective NK cell defect in maturation
Mice with NK-specific miR-15a/16-1 deletion (15a/16-1FKO) had normal NK cell percentages
and numbers in all organs examined. Additionally, in a complementary model of lymphocytespecific 15a/16-1 excision (hCD2-Cre),78,170 lymphocyte percentages, NK cell percentages, and
NK receptor repertoires were also normal. We hypothesized, due to miR-15/16’s predicted
targeting of cellular differentiation genes, that 15a/16-1FKO NK cells may have developmental
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defects. We therefore first analyzed early NK cell development in the BM, and found no
differences in early NK cell developmental precursor. We next examined established stages of
NK cell maturation in 15a/16-1FKO and Ctrl mice: CD27-CD11b- (stage I), CD27+CD11b- (stage
II), CD27+CD11b+ (stage III), and CD27-CD11b+ (stage IV). NK cell maturation was markedly
disrupted in 15a/16-1FKO mice (Figure 5.2A-B), predominantly in the stage III to stage IV
transition, when CD27 is down-regulated. Consistent with a maturation defect (and not a
selective alteration of CD27), CD43 expression also demonstrated an immature NK cell
phenotype. In the spleen, total NK1.1+CD3- NK cell numbers and percentages were unchanged
between 15a/16-1FKO and Ctrl mice; however, the number of NK cells at stage III was
increased, while stage IV was reduced, suggesting a block in maturation (Figure 5.2C). This
phenotype was consistent in other tissues examined (Figure 5.2D-E). Further, we also
confirmed these phenotypes in the hCD2-Cre model that exhibits lymphocyte restricted Cre
expression (hCD2-Cre x 15a/16-1F/F). Moreover, we were unable to detect any changes in the
death of stage IV NK cells from 15a/16-1FKO mice in vivo, suggesting that the change in
maturation stages was not due to reduced survival of stage IV NK cells (Figure 5.2F-G).
Therefore, miR-15a/16-1FKO NK cells exhibited a block in maturation from stage III to stage IV.
15a/16-1FKO NK cells have increased proliferative capacity and in vivo persistence
As the maturation defect was not caused by increased cell death of the stage IV NK population,
we next examined the possibility that altered proliferation of 15a/16-1FKO NK cells led to
skewing of NK cell maturation in these mice. We observed very low levels of proliferation
(detected by Ki-67 staining) in NK cells from adult mice analyzed directly ex vivo, suggesting
that constitutively increased proliferation in immature NK cells does not account for the
expansion of stage III NK cells. However, immature miR-15a/16-1FKO NK cells did have
significantly enhanced cytokine-induced proliferation when cultured in 100 ng/mL IL-15 ex vivo,
compared to controls (Figure 5.3A,B). In order to determine whether this effect also occurred
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during homeostatic proliferation of NK cells, we sorted immature (CD27+) YFP+ NK cells from
15a/16-1FKO or control mice, and transferred 5x104 into immunodeficient (RAG-/-γc) recipient
mice (Figure 5.3C). 15a/16-1FKO NK cells were found to proliferate with more rapid kinetics
(data not shown), and exhibited a durable increase in engrafted NK cell numbers over control
YFP+ NK cells (Figure 5.3D). Thus, 15a/16-1FKO NK cells have enhanced proliferation after
stimulation with IL-15 or after homeostatic proliferation, and enhanced long-term homeostasis.
15a/16-1FKO NK cells have defective functional ability due to maturation defects
We next investigated whether miR-15a/16-1 loss altered the function of NK cells. We found that
total NK cell IFN-γ responses to activating receptor ligation and cytokine receptor stimulation
were significantly diminished (Figure 5.4A,B). As a higher percentage of mature NK cells
produce IFN-γ in response to IL-12+IL-15 and α-NK1.1 stimulation, and the miR-15a/16-1FKO
mice lack these mature NK cells, this reduction was accounted for by comparing each
maturation stage for IFN-γ production (Figure 5.4C,D). However, these NK cells were still able to
produce control levels of IFN-γ when maximally stimulated by IL-12+IL-18. Thus, miR-15a/161FKO NK cells exhibit diminished IFN-γ responses, which was due to altered maturation.
miR-15/16 targeted mRNAs in NK cells
As miR-15/16 loss led to both decreased maturation in vivo and increased proliferation after in
vitro cytokine stimulation or adoptive transfer into an NK-deficient host, we sought to identify
relevant gene targets of miR-15/16 related to cellular proliferation or differentiation. Using
TargetScan and DAVID functional analysis, we found that miR-15/16 is predicted using
bioinformatics to target a number of genes in pathways involved in cell proliferation and
differentiation (BP00224) (Table S2), a number of which are expressed in NK cells 171.
We then experimentally evaluated mRNA differences between 15a/16-1FKO and control NK
cells using mRNA microarrays as an initial step toward identification of miR-15/16 targets in NK
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cells, acknowledging that this approach would omit miR-15/16 targets not regulated at the
mRNA level. Immature (CD27+) NK cells were sorted for this profiling experiment in order to
eliminate NK cell maturation biases in gene expression. We identified a number of modest, yet
significant, mRNA differences between the two genotypes. In order to enrich for genes directly
regulated by miR-15/16, we filtered the dataset for genes predicted to be targeted by miR-15/16,
and found three genes that were upregulated with a high degree of significance: Myb, Lats2,
and CD28. We validated that RNA levels of Myb and Lats2, but not CD28, were higher in miR15a/16-1FKO CD27+ NK cells by RT-qPCR (Figure 5.5B). Lats2 has previously been shown to
limit proliferation,172 which is inconsistent with observations in 15a/16-1FKO NK cells. In
contrast, Myb promotes cellular proliferation, and has been implicated in altering mature NK cell
percentages.74 We also found that by immunoblot analysis of CD27+ NK cells, Myb protein
levels were markedly increased, consistent with miR15/16 repression exhibiting a larger effect
on protein levels than RNA levels (Figure 5.5C). We therefore focused on Myb as a potential
mechanistic target for the NK cell maturation defect associated with miR-15/16 deficiency.
The transcription factor Myb is a direct target of miR-15/16, and Myb expression is down
regulated at later stages of NK cell maturation
Using a luciferase reporter assay, we next validated the direct repression of Myb by miR-15/16
(Figure 5.5D). Overexpressing or sequestering miR-15/16 miRNA levels resulted in decreased
or increased luciferase activity, respectively, when luciferase was fused to the Myb 3’UTR. Of
note, the two miR-15/16 binding sites present in the Myb 3’UTR are highly conserved between
mice and humans, and were energetically favorable targets for miRNA repression. We
assessed the levels of Myb in the different maturation stages of NK cells, and found that levels
of Myb were increased in CD27+ immature NK cells compared to CD27- (stage IV) mature NK
cells by RT-qPCR (Figure 5.5E) and immunoblot (Figure 5.5F). We next investigated Myb RNA
and protein expression in human NK cell subsets, and found that Myb expression was higher in
CD56bright NK cells as compared to the more mature, cytotoxic CD56dim NK cells. This suggests
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that Myb expression is regulated during NK cell maturation in multiple species. Thus, Myb is
directly targeted by miR-15/16, and is down regulated upon terminal NK cell maturation.
miR-15a/16-1FKO NK cells maintain a cell-intrinsic maturation defect after adoptive transfer
Ncr1 is also expressed in lymphoid tissue inducer (LTi), NK-22, and related cells (NarniMancinelli et al., 2011), and therefore we next confirmed the cell-intrinsic nature of the Ncr1-iCre
x miR-15a/16-1F/F maturation defect by adoptive transfer. Additionally, this adoptive transfer
system establishes an in vivo system for lentiviral manipulation and evaluation of primary NK
cell maturation (Figure 5.6A). We sorted immature stage II (CD27hiCD11blo) YFP+ NK cells from
Ctrl or 15a/16-1FKO mice, and transduced with a lentiviral construct overexpressing GFP to
track the NK cells. GFP+ lentivirus-transduced NK cells were sorted, expanded in IL-15, and
5x104 GFP+ NK cells were injected intravenously into recipient mice, and allowed to mature in
vivo for 10 days. The 10 day time point was chosen based on time course experiments, in order
to balance the time required for NK cells to mature in vivo with the loss of transferred NK cells
over time. The spleens from recipient mice were then harvested, and the transferred GFP+ NK
cells were analyzed for maturation (Figure 5.6B). We found that 15a/16-1FKO NK cells had
defective maturation after adoptive transfer (Figure 5.6C), confirming the cell-intrinsic nature of
the defect and establishing the validity of this system for the ectopic expression/repression
experiments in primary NK cells.
miR-15/16 overexpression or Myb knock-down in adoptively transferred 15a/16−1FKO NK cells
rescues NK cell maturation
In order to correct the aberrant overexpression of Myb in the miR-15a/16-1FKO NK cells, we
generated two vectors: 1) a lentiviral shRNA directed against Myb (GFP-Myb shRNA), which
was highly effective in repressing Myb protein expression, and 2) a lentiviral overexpression
construct for miR-15/16, which effectively restores miR-15a/16-1 and was similarly effective at
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repressing Myb protein expression. Both lentiviruses include GFP to mark transduced cells for
sorting and in vivo tracking.
Ctrl and 15a/16-1FKO CD27+CD11b- cells were transduced with viruses generated from these
constructs, adoptively transferred, allowed to mature for 10 days, and then evaluated for
maturation (Figure 5.6A-B). As expected, miR-15/16 reinstatement restored miR-15a/16-1FKO
NK cell maturation (Figure 5.6D). Additionally, Myb knockdown was able to restore the
maturation of the miR-15a/16-1FKO NK cells to comparable levels as replacement of miR-15/16
(Figure 5.6E). Therefore, miR-15/16’s direct targeting of Myb is crucial to NK cell maturation, as
15a/16-1FKO NK cell maturation can be rescued by either resupply of miR-15/16 or forced
downregulation of Myb.
Myb overexpression mimics the miR-15a/16-1FKO maturation defect
In order to specifically address the role of Myb in NK cell maturation, we cloned the Myb del10
isoform (Myb∆10), the major form of mouse Myb expressed in NK cells. The del10 isoform is
also the dominant from of Myb expressed in B and T cells,171 and shares 90% homology with
human Myb. We generated an overexpression construct for Myb∆10 (GFP-P2A-Myb), linked to
GFP via a P2A site, and verified that Myb is overexpressed via immunoblot.
In order to mimic the Myb overexpression in the 15a/16-1FKO NK cells, stage II Ctrl NK cells
were sorted, and transduced with either the GFP lentivirus or the GFP-P2A-Myb overexpression
lentivirus. GFP+ cells were sorted, expanded, injected i.v., and after 10 days NK cells were
harvested from the spleen and analyzed for NK cell maturation (Figure 5.6A,B). We found that
Ctrl stage II NK cells transduced to overexpress Myb had reduced maturation to Stage IV,
similar to the miR-15a/16-1FKO mice (Figure 5.6F). Therefore, forced Myb overexpression
prevented completion of NK cell maturation in vivo.
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Chapter 5: Discussion
The role of specific miRNAs in the regulation of NK cell development and maturation remains
largely unknown. To our knowledge this is the first report of an NK cell-specific miRNA deficit
that perturbs normal NK cell maturation. Using NK cell-restricted miR-15/16 genetic deficiency,
we show that reduced miR-15/16 expression resulted in a marked loss of the most mature
CD27−CD11b+ (Stage IV) compartment. Further, Myb was identified as a direct target of miR15/16 in immature NK cells, and is mechanistically responsible for the miR-15/16-deficient NK
cell maturation phenotype. These insights lead to new questions about the impact of Myb (and
Myb’s transcriptional targets) for proper NK cell maturation. Further, our study demonstrates
that NK cell-intrinsic genetic alterations of a miRNA family can expose novel aspects of the NK
cell molecular program.
This study reveals a critical role for miR-15/16, one of the most abundant miRNAs in NK cells, in
the regulation of NK cell maturation. miR-15/16 sequences are expressed from two loci in NK
cells, and expression remains constant throughout NK cell maturation (data not shown). The
deletion of the miR-15a/16-1 gene results in a modest (approximately 50%) relative reduction
compared to controls; however, due to its high expression in NK cells, its deletion results in a
large absolute change in the miRNA family expression. This resulted in clear biologically
significant alterations in downstream targets, in this case Myb, and in turn NK cell maturation.
Thus, at least for highly expressed miRNAs, a 2-fold change in expression can have substantial
biological effects in vivo. What are the consequences of complete loss of miR-15/16 family
members? Currently, miR-15b/16-2 conditional allele models required to address this issue in
concert with miR-15a/16-1 are not available for study. While other related family members are
present in NK cells, they are minimally expressed, and thus miR-15a, 15b, and 16 are the
relevant members of the miR-15/16 family for NK cells.
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We investigated the mRNA expression differences within immature NK cells between 15a/161FKO and control NK cells using microarrays, and identified modest changes with the 50%
reduction in miR-15/16. Despite the relatively low numbers of significant targets identified, this
analysis identified Myb and Lats2 as miR-15/16 targets, which were subsequently validated.
There are several potential explanations for the low number of miR-15/16 predicted targets
actually altered at the mRNA level in NK cells. First, miR-15/16 may predominantly exert its
effect on protein translation, rather than RNA degradation, supported by the much larger
increase in Myb protein expression (as compared to RNA expression) in the 15a/16-1FKO NK
cells. Second, target prediction for miR-15/16 is imperfect, and overestimates the number of
true biological targets. Third, our statistical power was too low to identify the small
transcriptional changes of some targets of miR-15/16, especially in the scenario of continued
miR-15b and miR-16-2 expression. Regardless, target mRNA level analysis does not provide a
comprehensive catalog of the miRNA targets or protein-level alterations in miR-15/16 deficient
NK cells. This finding highlights the importance of applying miRNA:mRNA target identification
techniques in the cell of interest, for example RISC-Seq/CLIP-SEQ,79,93,147 or proteomic,173
approaches. Such studies on NK cells will be most informative in the setting of complete miR15/16 ablation to maximize the ability to clearly identify miR-15/16 targets, and current efforts
include generation of miR-15b/16-2 floxed mice.
When miR-15/16 is deficient, Myb mRNA and protein levels are increased, correlating with
increased proliferation and disrupted stage III to IV maturation. Myb has been shown to be
involved in the proliferation of other lymphocytes,174 and therefore, increased proliferation in
15a/16-1FKO NK cells (with increased Myb) supports the role of Myb in lymphocyte
proliferation. However, as the proliferative rate of splenic steady-state NK cells is low, it does
not account for the maturation defect of 15a/16-1FKO NK cells. The implication of these findings
is that Myb must be down regulated in order for NK cells to complete maturation. Supporting
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these data, there is a large decrease in Myb mRNA levels during this final phase of maturation.
Further, 15a/16-1FKO NK cells that are able to mature to stage IV also have low levels of Myb.
Collectively, these observations support a model in which lack of miR-15/16 boosts Myb levels
in immature stage II/III NK cells, but NK cell maturation can still proceed, albeit at reduced
efficiency, if a critical threshold of Myb is reached, at which time Myb gene expression is
attenuated.
The identification of other factors that promote or inhibit the transcription and translation of Myb
in NK cells, which has a number of regulatory mechanisms,162 will further enhance our
understanding of NK cell maturation. Interestingly, other factors known to be required for NK cell
maturation are either stably expressed (Eomes, failure at stage II to III and T-bet, failure at III to
IV) or increased (Prdm1, failure at stage III to IV) throughout NK cell maturation.13,175 As Prdm1
is a transcriptional repressor that increases during maturation (while Myb is reduced), it will be
interesting to investigate whether Myb is downstream of Blimp1 regulated pathways.
Additionally, Myb levels are increased in the absence of Ets1, indicating that Ets1 may be
upstream of Myb, and this increased Myb expression may contribute to the maturation
phenotype in the Ets1-/- mouse.14
Myb has been previously shown to have a role in the differentiation of lymphocytes and other
cells, and is known to be targeted by miR-150 in NK cells.74 Notably, the Myb 3’UTR is predicted
to be regulated only by these two miRNA families, when the prediction analysis is limited to
miRNAs expressed in abundance in resting NK cells. We investigated the combined effect of
miR-150 and miR-15/16 on Myb, given that the two miRNAs target distinct sites in the 3’UTR of
Myb, but found no additive or synergistic effect using an in vitro luciferase assay (data not
shown). However, this does not exclude an in vivo cooperation of these two miRNAs at
physiologic expression levels, and it will be interesting to investigate miR-150 and miR-15/16
cooperation in vivo as models become available. Interestingly, while miR-150 deficiency was
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shown to decrease IFN-γ production – an effect that was not explained by the maturation
change in those mice,74 miR-15a/16-1 deficiency reduces overall IFN-γ production exclusively
through altered maturation. Further, altered miR-150 dosage led to additional effects on NK
cells, for example an altered Ly49A expression, an effect that was not observed in the miR15a/16-1FKO. Moreover, while NK cells from miR-15a/16-1FKO exhibited enhanced
proliferation, this effect was not observed in the miR-150-/-. This suggests that while these highly
expressed miRNAs have distinct pleiotropic sets of targets in NK cells, there may be targeting
overlap for selected mRNAs, such as Myb.
There is published literature describing Myb targets;176–178 however, many of these studies have
been performed in cell lines, and have unknown relevance to NK cell biology. Currently, Myb
CHiP-Seq experiments in NK cells are limited by the lack of highly specific anti-Myb antibodies
for immunoprecipitation. Of the validated targets of Myb: Myc, CCNB1, CCNE1, and Kit (but not
Bcl2, Gata3, or Hspa5) show a transcript reduction during maturation and correlating to Myb
loss.12 To our knowledge, the role of Myc has not been investigated in NK cell maturation, but
has been shown to be critical in the regulation of NK-T cell differentiation,179,180 and to play a
role in NK cell transformation following supra-physiologic IL-15 exposure.181 Cross-regulation
between Myb, Myc, and other transcriptional regulators in governing the role of NK cell
maturation is an intriguing possibility.
Our findings that Myb expression is differentially regulated in human CD56bright and CD56dim
subsets are consistent with the model that CD56bright are less differentiated than CD56dim NK
cells. The miR-15/16 binding sites in the Myb 3’UTR are highly conserved, resulting in parallel
regulation of Myb by miR-15/16 in both species. Thus, our data in mice, and species
conservation between miR-15/16 and Myb in mouse and humans, suggest that miR-15/16
control of Myb may regulate human NK cell differentiation. However, this is challenging to
experimentally interrogate, since there are differences in Myb family expression between mice

118

and humans, with the additional Myb family member Mybl1 being significantly expressed in
human, but not mouse, NK cells.171 Our future studies will seek to test the hypothesis that miR15/16 similarly targets Myb in human NK cells, and thereby regulates human NK cell maturation.
In summary, the regulation of Myb by miR-15/16 is essential for complete NK cell maturation,
revealing a novel mechanism regulating NK cell development. In agreement with these data,
immature mouse NK cells transduced to overexpress Myb fail to mature in vivo, and 15a/161FKO NK cells fail to mature due to increased levels of Myb, which can be corrected either by
reintroducing miR-15a/16-1 or siRNA-mediated reduction of Myb. These data reveal a novel
miRNA – transcription factor regulatory pathway that controls normal NK cell maturation in vivo.
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Figure 5.1
miR-15/16 is highly expressed in NK cells, and miR-15a/16-1 is efficiently and specifically
deleted upon Cre-mediated excision.
(A) Illumina miR-Seq of miRNAs families contributing to more than 1% of the overall miRNA
sequences in resting mouse NK cells. miR-15/16 (consisting of miR-15a, miR-15b, and miR-16)
is highlighted in blue.
(B) Diagram of 15a/16-1FKO mice, consisting of a LoxP-flanked (triangle) 15a/16-1 allele,
combined with an Ncr1-iCre and a Rosa-LSL-YFP allele, which expresses YFP after Cremediated excision (not shown). This model eliminates miR-15a and miR-16-1 expression, but
leaves miR-15b and miR-16-2 expression intact.
(C) RT-qPCR of the major miR-15/16 family members (miR-15a, miR-16, miR-15b) in Ctrl and
15a/16-1FKO YFP+ NK cells and YFP- T cells. Error bars indicate SEM of duplicate
measurements from three independent experiments. ***p<0.001 by t-test.

120

% of Total miRNA

A

30

20

10

m
iR
m 21
iR
m -14
2
iR
-1
5/
16
le
tm 7
iR
-2
m 9
iR
-2
m 6
iR
-2
m 4
iR
m 22
iR
m 15
0
iR
-1
7/
m 92
iR
m 342
iR
-1
m 46a
iR
-1
46
a

0

B
Chromosome
14

DLEU2
Exon 4

15a

16-1

DLEU2
Exon 5

Chromosome
3

Smc4
Exon 5

15b

16-2

Smc4
Exon 6

Net miR-15/16
Ctrl (Ncr1-iCre x 15a/16-1WT/WT)

miR-15a

15a/16-1FKO (Ncr1-iCre x 15a/16-1F/F)

Relative Expression

C
1.5

miR-15a

1.5

miR-16

1.5

miR-16-1 miR-16-2

miR-15b

miR-16-2

100%
50%

miR-15b
ns

***

***

miR-15b

1.0

1.0

0.5

0.5

0.5

0.0

0.0

0.0

1.0

Ctrl

NK

T

NK

T

15a/16-1FKO

NK

121

T

Figure 5.2
miR-15/16 deletion results in defective NK cell maturation.
(A-B) Representative flow cytometry (A) and summary data (B) of maturation (CD27 x CD11b)
of Ctrl (top) and 15a/16-1FKO (bottom) splenic YFP+ NK cells. Error bars indicate SEM of two
independent experiments. ***p<0.001 by t-test.
(C) Summary data of the number of NK cells at each stage in maturation. Error bars indicate
SEM of two independent experiments. *p<0.05; **p<0.01 by t-test.
(D-E) Representative flow cytometry (D) and summary data (E) of maturation (CD27 x CD11b)
of Ctrl (top) and 15a/16-1FKO (bottom) YFP+ NK cells from the indicated organs. Data are
representative of (D) or summarized from (E) three independent experiments.
(F-G) Representative flow cytometry (F) and summarized data (G) of cell death (7-AAD+) of total
(YFP+ and YFP-) NK cells. YFP- cells are included in this analysis because YFP expression is
lost during cell death. Maturation stages (except for rare CD27-CD11b- Stage I cells) were
analyzed separately for cell death. Data summarize two independent experiments.
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Figure 5.3
15a/16-1FKO NK cells exhibit increased proliferation and prolonged in vivo persistence.
(A-B) Representative flow cytometry (A) and summary data (B) of proliferation (Ki-67+) of Ctrl
(top) and 15a/16-1FKO (bottom) splenic YFP+ NK cells after 24 hours of culture in 100 ng/mL
IL-15. This stimulation condition was used after finding low levels of proliferation in vivo. Error
bars indicate SEM of two independent experiments. *p<0.05; **p<0.01 by t-test.
(C-D) 15a/16-1FKO donor NK cells have prolonged in vivo persistence. 5e4 YFP+CD27+CD11bNK cells from Ctrl or 15a/16-1FLO were injected into RAG-/-γc-/- recipient mice (C), and
peripheral organs (blood, spleen) were analyzed 35 days post-transfer (D). Data summarize two
independent experiments. *p<0.05 by t-test.
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Figure 5.4
15a/16-1FKO NK cells have decreased function due to maturation defects.
(A-B) IFN-γ production by 15a/16-1FKO and Ctrl NK cells. Representative flow after stimulation
with α-NK1.1 (A), and summary data after stimulation with α-NK1.1, IL-12+IL-15, and IL-12+IL18 (B).
(C-D) IFN-γ production by maturation subsets of 15a/16-1FKO and Ctrl NK cells. Representative
flow after stimulation with IL-12+IL-15 (C) and summary data after stimulation with α-NK1.1, IL12+IL-15, and IL-12+IL-18 (D). Data are representative of (A,C) or summarize (B,D) three
independent experiments.
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Figure 5.5
Myb is more highly expressed in 15a/16-1FKO NK cells, is directly targeted by miR-15/16,
and is more abundant in immature NK cells.
(A) Gene1.0ST microarray of three independently generated groups of CD27+ (immature)
15a/16-1FKO and Ctrl NK cells, filtered based on predicted miR-15/16 targeting. Dashed lines
indicate no change (vertical) and p<0.05 (horizontal).
(B-C) RT-qPCR (B) and Western Blot (C) of Myb expression in YFP+ Ctrl or YFP+ 15a/16-1FKO
NK cells of the indicated maturation stage. Data in (A) summarize three independent
experiments, data in (B) are representative of two independent experiments. *p<0.05 by t-test.
(D) Luciferase assay for Myb 3’UTR v. No 3’UTR, with overexpression of GFP (no miRNA),
GFP-miR-15/16 (+miR-15/16) or GFP-miR-15/16 Sponge (miR-15/16 Sponge) that reduces
available mature miR-15/16 in HEK293T cells. Data are normalized to the No 3’UTR + No
miRNA condition. Transfection efficiency as measured by GFP+ cells was >80% in all
experiments. Data summarize 2 independent experiments. ***p<0.001 by t-test.
(E-F) RT-qPCR (E) and Western Blot (F) of Myb expression in YFP+ Ctrl NK cells of the
indicated maturation stage. Data in (E) summarize 3 independent experiments, data in (F) are
representative of two independent experiments. *p<0.05 by one-way ANOVA, ***p<0.001 by
one-way ANOVA.
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Figure 5.6
miR-15/16-deficient NK cells fail to mature due to increased Myb levels.
(A) Overview of experimental system, in which immature (CD27+CD11b-) YFP+ NK cells are
sorted, transduced with indicated lentiviruses (Ctrl with GFP only, GFP-15/16, or GFP-P2A-Myb;
15a/16-1FKO with GFP only, GFP-15/16, or GFP-Myb shRNA), and sorted for GFP+ cells after
two days of culture. After sorting, cells were expanded for 6-10 days in IL-15, and 5x104 cells
were injected into recipient mice. After 10 days, spleens from recipient mice were harvested and
analyzed for donor GFP+ NK cells.
(B) Representative flow cytometry plots of adoptively transferred NK cells.
(C-F) Summary data of Ctrl vs. 15a/16-1FKO NK cells transduced with the GFP only virus (C),
15a/16-1FKO NK cells transduced with GFP only or with the GFP-15/16 virus to restore miR15/16 levels (D), 15a/16-1FKO NK cells transduced with GFP only or with GFP-Myb shRNA to
reduce Myb levels (E), and Ctrl NK cells transduced with GFP only or GFP-P2A-Myb to mimic
the Myb overexpression phenotype of the 15a/16-1FKO (F). Data summarize 3-4 experiments,
using the same controls (GFP only) for multiple panels (C and E share the Ctrl GFP only
control, while C, D, and E share the 15a/16-1FKO GFP only control). One experiment of 15a/161FKO + GFP in (D) did not have a corresponding 15a/16-1FKO + GFP-15/16, and the control in
this panel is censored. *p<0.05 by paired t-test.
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Chapter 6: Discussion and Future Directions
The new findings presented here support diverse and important roles for miRNAs in NK cells: in
a global fashion (Chapter 3), as well as specific roles for miR-155 in NK cell function (Chapter 4)
and miR-15/16 in NK cell maturation (Chapter 5).
These findings demonstrate that as a group, miRNAs support survival and maturation, and
inhibit effector function; that is, while a few miRNAs likely inhibit survival and promote effector
function, the bulk effect of miRNAs is to support NK cell survival and maturation and oppose
function. Besides miR-155 and miR-15/16, which were identified using expression screens with
and without activation, there are several other highly expressed candidate miRNAs that likely
have roles in NK cell survival, maturation and function, including miR-150, miR-21, miR-142,
and the let-7 family, among others.
We found that miR-155 has a dual role in setting the threshold for NK cell activation during
development by downregulating the expression of key members of the PI3K and calcineurin
pathways, as well as increasing the level of activation of NK cells currently responding to
stimulation, likely through downregulation of SHIP1, a negative repressor of activation. These
findings give us a greater understanding of the mechanisms by which the NK cell activation
threshold is determined, as well as a better understanding of how to maximally activate NK
cells. These studies would suggest that NK cells that lack miR-155 during an initial activation
period, when threshold is determined, or that overexpress miR-155 during subsequent
stimulation, would be better responders to stimulus. However, it is important to consider these
results with the caveat that these studies were performed on a global miR-155 deletion mouse.
A conditional (LoxP-flanked) miR-155 allele is now available, and it will be important to validate
these studies in that model. A conditional model, with miR-155 deleted only in NK cells, will
further allow a number of long-term miR-155 deficiency studies, including NK cell responses to
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tumor models and survival after MCMV infection. A number of studies have recently
demonstrated that NK cells that have previously been activated have “memory” of that prior
activation, and respond better to later stimulation.182–184 It will be interesting to see if miR-155
plays a role in this complicated and poorly understood process. It will further be interesting to
determine if miR-155 overexpression can enhance NK cell activation, as a potential use for antitumor therapies, as was recently shown in a mouse model of miR-155 transgenic
overexpression.73
We demonstrated that miR-15/16, a highly expressed miRNA in NK cells, directly represses the
transcription factor c-Myb, which must be downregulated in order for NK cell maturation to
proceed to the final stages of NK cell maturation. Indeed, when Myb is forcibly overexpressed in
immature NK cells, the NK cells fail to mature, while maturation in NK cells that lack miR-15/16
(and thus overexpress c-Myb) can be corrected by shRNA-knockdown of c-Myb. Thus, c-Myb is
the causative factor of the maturation defect in miR-15a/16-1FKO NK cells, demonstrating that
miR-15/16’s targeting of Myb is crucial to appropriate NK cell maturation. Additionally, the highly
expressed miR-150 also targets c-Myb, highlighting the importance of this transcription factor in
NK cells.
However, c-Myb’s role as a transcription factor remains unexplored in NK cells. What transcripts
is it promoting or repressing? Other genes previously demonstrated to be direct targets of c-Myb
in other cell types do not point to immediately obvious targets that could further affect
maturation. In future experiments, CHIP-Seq of Myb in immature NK cells, as well as RNA
micro-array of NK cells lacking Myb, or NK cell lines overexpressing c-Myb, will help to
determine the relevant targets of c-Myb that are involved in NK cell maturation. The c-Myb-/- is
embryonic lethal, so a conditional Ncr1-iCre x c-MybLoxP/LoxP model will have to be generated in
order to address the hypothesis is that NK cells that lack c-Myb expression will either have NK
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cells with increased maturation, or a decrease in NK cell numbers due to an early requirement
for Myb.
The role of miRNAs in NK cells has become clearer in recent years, in part due to these studies.
However, a great deal remains to be understood: what regulates the expression of miRNAs in
NK cells? What pathways do miRNAs converge on? What are the cell-context specific targets of
miRNAs in NK cells, and how do these differ from other cells? What are the effects of these
differences? How does the expression of miRNAs change during NK cell development,
maturation, and activation? Do different activation conditions promote different miRNA
expression profiles? What are the effects of the other highly expressed miRNAs in NK cells,
such as miR-150, miR-21, miR-142, and others? Answering these questions, and the many
others brought up by these studies, will be key to our understanding of fundamental NK cell
biology.
Furthermore, understanding these questions may one day allow manipulation of these miRNAs
in NK cells in vivo. Already, therapeutic strategies based on the systemic administration of
miRNAs has shown promise in the treatment of cancer.185 Targeted siRNA strategies are
entering the clinic, and have been shown to have highly favorable kinetics and potency.186 One
might imagine that miRNAs could have increased utility over siRNAs in cases in which a miRNA
targets a particular pathway, such as miR-155’s targeting of NK cell activation pathways.
Indeed, miR-31 has been recently shown to act in a pleiotropic manner to inhibit breast cancer
metastasis.187 Could targeted introduction of miR-155 into mature NK cell boost their anti-tumor
and anti-viral abilities? Could targeted knockdown of Myb in NK cells induce maturation,
allowing the cells to become more potent anti-tumor and anti-viral effectors?
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It is hoped that these studies will form a basis for future investigation, ultimately leading to the
improved understanding of the generation, maturation, and activation of these highly potent,
anti-tumor and anti-viral effector NK cells.
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